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The key goals for the development of new anti-mycobacterial drugs are to shorten the 
treatment time and to have efficacy against latent as well as multi-drug resistant 
tuberculosis.  The best drug targets should be essential in both active and dormant phases 
of the Mycobacterium tuberculosis infection, so that a single drug would eradicate both 
populations.  The only feasible way to elucidate such a novel target is to use a forward 
chemical genetics approach.  Forward chemical genetics involves screening a library of 
compounds against the entire proteome for novel targets whose inhibition by one of the 
compounds results in bacterial death or growth inhibition.  The candidate drug/target pair 
can be identified by microarray fingerprinting (Boshoff et al., 2004), proteomic profile 
comparison as well as whole genome sequencing of spontaneous resistant mutants (Andries 
et al., 2005).   
 
We isolated M. bovis BCG mutants resistant to two structurally-related compounds, named 
compound X and compound Y.  The magnesium and cobalt transport transmembrane 
protein, CorA, was identified as a putative target of these two compounds.  This was based 
on the mapping of genetic mutations to the corA gene from the compound-resistant mutant 
strains.  Moreover, the exogenous expression of the mutant copy of corA gene in wild-type 
mycobacteria conferred high levels of resistance to these two compounds.  However, due to 
the non-essentiality of the corA gene and the bactericidal effect of the compounds, we 
suggest that CorA is not the actual target and that it mediates an indirect mechanism of 
resistance.  More experiments are needed to identify and validate the biological target of 
compound X and compound Y. 
IX 
List of Tables 
 
Table 1.1:  Current anti-tuberculosis drug targets with specific examples ........................17 
Table 1.2: Technologies that can be used to identify the biological target of 
compounds .......................................................................................................21 
 
Table 2.1:  List of primers used for sequencing, expression and gene deletion 
constructs .........................................................................................................30 
 
Table 3.1: Anti-mycobacterial properties of CpdX and CpdY against wild-type 
M. bovis BCG and M. smegmatis.....................................................................41 
 
Table 3.2:  Mutation frequency experiment for CpdX and CpdY in wild-type 
M. bovis BCG and M. smegmatis.....................................................................42 
 
Table 3.3:  The MIC50 values for 23 standard drugs against wild-type M. bovis 
BCG and M. smegmatis ...................................................................................44 
 
Table 3.4:  Cross-resistance study of CpdX and CpdY-resistant M. bovis BCG and 
M. smegmatis mutants......................................................................................45 
 
Table 3.5:  CorA mutations found in all the sequenced CpdX and CpdY-resistant 
M. bovis BCG and M. smegmatis mutants.......................................................49 
 
Table 3.6:  Summary of 2D gel electrophoresis experiments ............................................55 
X 
List of Figures 
 
Figure 3.1:  Results of Comparative Genome Sequencing..................................................48 
Figure 3.2:  Expression of corA gene in wild-type M. bovis BCG......................................51 
Figure 3.3: Comparison of the corA sequences from various mycobacteria ......................52 
Figure 3.4: Example of protein identification by LC-MS; with analysis using 
MASCOT and X! Tandem...............................................................................56 
 
Figure 3.5: 2D gel electrophoresis (18cm pH 4-7 strips) ...................................................57 
Figure 3.6: 2D gel electrophoresis (18cm pH 4-7 strips) – close up 1...............................58 
Figure 3.7: 2D gel electrophoresis (18cm pH 4-7 strips) – close up 2...............................59 
Figure 4.1: Target theory versus mode of entry theory ......................................................64 
Figure 4.2: Target versus Transporter theory when M. bovis BCG is complemented 





List of Abbreviations 
 
2D Two-dimensional 
AIDS Acquired Immunodeficiency Syndrome 
BCG bacille Calmette-Guérin 
CDC Centers for Disease Control and Prevention 
CFUs Colony Forming Units 
CpdX Compound X 
CpdY Compound Y 
DOTS Directly Observed Treatment Short Course 
HIV Human Immunodeficiency Virus 
HTS High-Throughput Screening 
LC-MS Liquid Chromatography-Mass Spectrometry 
MBC Minimum Bactericidal Concentration 
MDR-TB Multi-Drug Resistant Tuberculosis 
[Mg2+] Concentration of Magnesium 
MIC Minimum Inhibitory Concentration 
OD600 Optical Density at a wavelength of 600nm 
PCR Polymerase Chain Reaction 
PPD  Purified Protein Derivative 
SNPs Single Nucleotide Polymorphisms 
WHO World Health Organization 






























The first part (Section 1.1 to Section 1.7) of this chapter will cover the clinical, 
epidemiological and scientific information about the disease tuberculosis and its 
causative agent.  In the later parts, the use of chemical genetics to identify a compound 
that targets a novel biological target and the tools available for identifying such a target 
is presented (Section 1.8 to Section 1.11). 
 
1.1. Tuberculosis 
Tuberculosis is a contagious disease caused mainly by Mycobacterium tuberculosis 
and sometimes M. bovis.  M. tuberculosis is a relatively large, non-motile, rod-shaped, 
acid-fast bacillus belonging to the family of actinomycetes (Parish and Stroker, 1998).  
M. tuberculosis is an obligate intracellular parasite.  In the laboratory, M. tuberculosis 
can be grown on the agar-based Middlebrook medium or the egg-based Lowenstein-
Jensen medium (Parish and Stroker, 1998).  Since it has a slow generation time of 
around 18-20 hours, it takes 3-6 weeks for the bacteria to form visible colonies on 
these solid media (Parish and Stroker, 1998). 
 
1.2. Epidemiology 
In the 19th century in Europe, tuberculosis, then known as the White Plague, was 
responsible for 30% of total mortality (Merck, 2003).  The World Health Organization 
(WHO) estimates that globally two billion people are latently infected with 
tuberculosis and that nine million people develop active disease annually, of which 
two million die each year (Dye et al., 2006; Dye et al., 1999).  M. tuberculosis 
infections have reemerged as a major public health problem around the globe because 
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of poverty, neglect of the disease in the developed world, poor health services during a 
crisis, migration of people from endemic countries, multi-drug resistant tuberculosis 
(MDR-TB), and, lastly, due to HIV co-infection (Dye et al., 2006; Grange and Zumla, 
1999; Manganelli et al., 2004; Espinal et al., 2001; Raviglione et al., 1997). 
 
The WHO estimates that 90% of the tuberculosis cases occur in the developing world 
(50% of those in the sub-Saharan desert region (Zumla et al., 2000; WHO, 2004)) 
where the disease predominantly affects the 15-54 years age group.  This has a severe 
economic impact on the patient’s family and his/her community.  Tuberculosis disease 
results in the loss of, on average, 20-30% of annual income or 15 years of income if 
the disease results in death (WHO, 2004; Ahlburg, 2000).  In contrast, in the developed 
world the disease often occurs in the elderly or immunodeficient individuals. 
 
Tuberculosis is classified as MDR-TB when the bacilli are resistant to at least the two 
front-line drugs rifampicin and isoniazid.  MDR-TB is on the rise in many parts of the 
world, especially in the former Soviet Union (Espinal et al., 2001).  In 2006, the 
outbreak of a virulent XDR-tuberculosis (eXtensively Drug-Resistant; i.e. MDR-TB 
that is additionally resistant to three or more second-line drugs) strain in South Africa 
where 52 out of 53 patients died within one month of diagnosis further highlights the 




1.3. Biology of tuberculosis 
1.3.1. Immunology of tuberculosis 
Infection of humans via the aerosol route with M. tuberculosis will result in latent or, 
sometimes, active tuberculosis.  Clinically, the primary infection could be controlled 
entirely by the innate immune system and the infected individuals remain 
asymptomatic (Grosset, 2003).  However, the infection can also progress to a latent 
state with a 10% lifetime chance of reactivation to active disease (Gedde-Dahl, 1952; 
Grosset, 2003) (see Section 1.3.5. Persistence and Latent Tuberculosis). 
 
1.3.2. Clearing of primary infection by the immune system 
Most commonly, M. tuberculosis spreads when an infected patient expels small 
droplets that contain the bacilli during sneezing, coughing or talking (Merck, 2005).  
The most infective droplet is around 1-3µm in diameter (large droplets do not remain 
airborne for long and do not reach the alveoli to establish an infection) and contains up 
to three bacilli (Riley, 1974; Riley et al., 1962; Grosset, 2003).  One to three weeks 
following infection, the bacilli multiply exponentially in the macrophages, which at 
this stage are not activated hence cannot effectively kill the mycobacteria (McDonough 
et al., 1993; it should be noted that dendritic cells can also phagocytose mycobacteria 
(Bodnar et al., 2001)).  Subsequently, cellular immunity becomes activated when 
infiltrating CD4+ T-lymphocytes recognize the M. tuberculosis antigens presented on 
MHC (Major Histocompatibility Complex) molecules of antigen presenting cells and 
release cytokines (such as γ-interferon) that activate the macrophages (Grosset, 2003).  
In addition, CD8+ T-lymphocytes can also eliminate the infected macrophages 
(Houben et al., 2006).  Humoral immunity is ineffective against mycobacteria because 
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the bacilli are intracellular and, even when the bacilli are in extracellular spaces, the 
thick cell wall prevents complement-mediated antibody killing. 
 
At this stage, granulomas start to form at the foci of infection (see Section 1.3.2. 
Granuloma Formation and Caseous Necrosis; Grosset, 2003).  Some bacilli may 
survive in this region of caseous necrosis for years (see Section 1.3.5. Persistence and 
Latent Tuberculosis).  Occasionally, the bacilli may spread to other parts of the lung or 
to any part of the body via the bloodstream (see Section 1.3.5. Extrapulmonary 
Tuberculosis; Merck, 2005). 
 
It should be noted that in an immunocompetent host, the infection does not always 
result in active disease (only 10% develop tuberculosis) (Enarson and Rouillon, 1994).  
The lesions heal to form either the fibrous, calcified Ghon complex (in the primary 
foci), nodular Simon foci (in other smaller foci) or calcified lymph nodes (Merck, 
2005). 
 
1.3.3. Granuloma formation and caseous necrosis 
Tuberculous granulomas are a special type of lesion associated with tuberculosis 
disease.  It consists of caseous necrosis in the center of the lesion surrounded by giant 
multinucleated Langhan’s cells, epitheloid cells (activated macrophages), lymphocytes 
and fibroblasts (Canetti, 1955; Opie and Aronson, 1927; Adams, 1976; Bouley et al., 
2001; Grosset, 2003; Cosma et al., 2003).  Caseation (derived from the word caseum 
which means cheese) is a typical type of amorphous necrotic lesion that is associated 
with tuberculosis (Canetti, 1955; Opie and Aronson, 1927; Grosset, 2003).  As these 
lesions develop, there is a huge reduction in the bacillary load within these lesions.  In 
6 
the old caseous foci, there are very little, if any viable bacilli (Canetti, 1955; Opie and 
Aronson, 1927; Grosset, 2003). 
 
Caseous necrosis results from the infiltration of activated cytotoxic T-lymphocytes that 
kill macrophages (or its derivatives the Langhan’s giant cells and epitheloid cells) 
infected with M. tuberculosis as part of a necessary process to control the unimpeded 
bacillary replication (Grosset, 2003).  This immunological activity damages the host 
tissue, but at the same time destroys a majority of bacteria.  However, the bacilli do 
survive extracellularly but cannot replicate because of low oxygen tension, acidic 
environment within the caseous foci (Grosset, 2003).  These physiological conditions 
may prompt the tubercle bacilli to enter a state of non-replicating persistence (or 
dormancy).  This population of non-replicators is believed to be responsible for the 
long treatment period of over six months (see Section 1.6. Prevention, current 
treatment, DOTS and drug resistance). 
 
In up to 90% of infected individuals, the T-cell activated macrophages will form the 
granulomas and eventually eliminate most of the bacteria.  Sometimes, the caseation 
softens, spreads into the bronchial tree, and forms a lung cavity (see Section 1.3.4. 
Lung cavity) where the bacilli multiply exponentially following exposure to high 
oxygen levels (Canetti, 1955; Enarson and Rouillon, 1994).  The softening of the 
caseum into the large airways of the lungs progresses asymptomatic M. tuberculosis 
infection into active tuberculosis disease.   
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1.3.4. Lung cavity 
Lung cavities are the result of the softening of the caseum that is released into the 
bronchial tree, which in turn allows the bacilli to grow extracellularly due to the 
oxygen-rich environment (Long, 1935).  A patient becomes infectious at this stage of 
the disease when thousands of bacilli in the lung cavity are released as small droplets 
during coughing or sneezing.  Before the advent of antibiotics, around a quarter of all 
immunocompetent patients with lung cavities control the disease via cell-mediated 
immunity (see Section 1.3.3. Granuloma formation and caseous necrosis; Enarson and 
Rouillon, 1994).  Half of the untreated patients that develop cavitary tuberculosis die 
within the first two years because bacilli released from the lung cavity will form new 
granulomas and in due course destroy the entire lung (Enarson and Rouillon, 1994).  
The remaining 25% of patients that do not receive any treatment will develop a chronic 
tuberculosis infection.  
 
1.3.5. Extrapulmonary tuberculosis 
Infection of tuberculosis outside the lung can also occur, due to the spread of bacilli 
either by the bloodstream or uncontrolled infection in the lung that spreads to nearby 
organs (Merck, 2005).  Miliary tuberculosis is a severe form of tuberculosis where 
there is a widespread dissemination of bacteria throughout the body, presumably when 
the infection destroys the blood vessel walls thus releasing bacilli into the bloodstream 
(Merck, 2005).  This form of tuberculosis is often fatal if left untreated.  Tubercle 
bacilli can also infect the peritoneum, genitourinary system, pericardium, lymph nodes, 
bones, joints, gastrointestinal system, liver and meninges with varying degrees of 
severity and clinical outcomes (Merck, 2005).  For example, tuberculous meningitis is 
associated with high morbidity and mortality in young children (Merck, 2005). 
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1.3.6. Persistence, dormancy and latent tuberculosis 
Latent tuberculosis is a clinical condition where an individual is not sick with active 
tuberculosis but is purified protein derivative (PPD)-positive (see Section 1.5. 
Diagnosis of active and latent tuberculosis).  As early as 1952, Gedde-Dahl described 
the latency phenomenon and this observation was confirmed by fact that a patient 
developed tuberculosis after 33 years of latent infection (Lillebaek et al., 2002).  The 
World Health Organization currently estimates that two billion people are latently 
infected with M. tuberculosis, with the vast majority showing no symptoms or disease 
(Dye et al., 1999).  Despite this, there is still an ongoing discussion as to the true 
nature of latency and how low bacillary numbers are maintained for many years.  
Specifically it is uncertain if the M. tuberculosis enters a dormant state, or that a fine 
balance between replication of the bacilli and its elimination by the host immune 
system is achieved (Parrish et al., 1998 Cosma et al., 2003).   
 
1.3.6.1. The nature of persistence (dormancy) of mycobacteria 
There is a theory among researchers that latent tuberculosis is the result of the bacteria 
lowering their metabolism and entering into a non-replicative state (also known as 
dormancy).  This theory supported by several pieces of compelling evidence.  One, no 
bacteria could be cultured when infected tissues containing acid-fast bacilli were used 
as the inoculum (Manabe and Bishai, 2000, McKinney, 2000, Parrish et al., 1998 and 
Cosma et al., 2003).  It should be noted that the tissues were isolated from tuberculosis 
patients undergoing treatment and it is not unconceivable that drug-treated M. 
tuberculosis do not grow well under in vitro conditions.  Two, despite sufficient 
penetration of antibiotics in the diseased tissue, it is well known that under in vitro 
conditions the bacilli are killed quickly, yet in human beings, a long course of therapy 
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is required (McKinney, 2000; Mitchison, 1979; Cosma et al., 2003).  Nevertheless, the 
bacilli may have divide occasionally during the latent stage because isoniazid (a 
known cell-wall synthesis inhibitor; see Table 1.1) can decrease the risk of tuberculosis 
reactivation in PPD-positive patients (Comstock et al., 1979; Cosma et al., 2003).   
 
1.3.6.2. Hypoxia-induced non-replicating persistence in M. tuberculosis –  the 
Wayne Model 
Many in vitro models have been developed to induce non-replicating persistence in 
M. tuberculosis.  These include models based on altering the pH, nutrient starvation, 
hypoxia and nitric oxide levels (Dickinson and Mitchison, 1981, Heifets and 
Lindholm-Levy, 1992, Betts et al., 2002, Nathan and Shiloh, 2000; Wayne and 
Sohaskey, 2001).  In particular, the hypoxia-induced Wayne model has been studied 
and established in great detail (Wayne and Sohaskey, 2001).  Although oxygen levels 
within granulomas have not been determined, there is ample evidence to suggest that 
latent tuberculosis is the result of the survival of M. tuberculosis in an oxygen-
deficient environment.  Infection and reactivation is most commonly associated with 
the superior lobes of the lung where the oxygen tension is higher (Adler and Rose, 
1996).  Moreover, non-dividing bacilli can remain viable without oxygen in a 
presumably dormant state for several years (Canetti, 1955; Corper and Cohn, 1933). 
 
In the Wayne model, mycobacteria are grown in sealed glass tubes with magnetic 
stirrers under a defined head space ratio of 0.5.  The constant stirring ensures a uniform 
distribution of cells throughout the Dubos medium in such a way that the oxygen in the 
head space is slowly depleted to create a three-stage growth curve.  The bacterial 
growth can be monitored by measuring the absorbance of the cultures periodically.  
10 
The bacteria grow exponentially for the first 5 days due to the presence of dissolved 
oxygen in the medium.  The shift into the first stage of non-replicating persistence 
phase 1 (NRP1) occurs as the dissolved oxygen levels reach around 1%.  NRP1 is 
characterized by a slight increase in turbidity without a concomitant increase in the 
bacterial colony forming units (CFUs).  At day 10, the methylene blue indicator starts 
to fade and the decolorization is complete by day 12.  This stage of non-replicating 
persistence phase 2 (NRP2) occurs when the oxygen level reaches 0.06% of normal 
saturation (anaerobic) and no further increase in optical density is seen (Wayne and 
Hayes, 1996; Wayne and Sohaskey, 2001).  The bacteria from NRP2 show phenotypic 
isoniazid resistance. 
 
1.3.6.3. Evidence of bacilli in the tissues of healthy PPD-positive individuals 
These latent bacilli have been found in humans albeit in very low numbers.  A few 
CFUs were isolated from pathologically normal lungs of people who had died from 
unrelated causes (Canetti, 1955; Feldman and Baggenstoss, 1938; Opie and Aronson, 
1927; Grosset, 2003).  Using in-situ PCR, M. tuberculosis DNA was found in the lung 
samples of individuals from Ethiopia and Mexico; both countries have a high 
prevalence of tuberculosis (Hernandez-Pando et al., 2000).  Moreover, as noted earlier, 
isoniazid significantly reduced the risk of disease in PPD-positive people suggesting 
that there must be viable bacilli within the lung tissue (Comstock et al., 1979; IUAT, 
1982).  Moreover, hypoxic bacilli within tuberculosis lesions were imaged in vivo 
using pimonidazole probing (Barry et al., Tanzania, 2005). 
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1.3.6.4. Use of in vitro models of dormancy in drug discovery 
The current drugs affect processes essential during replication and active metabolism, 
such as protein and cell wall synthesis, but show little or no activity against quiescent 
bacilli (see Section 1.8. Essential drug targets in M. tuberculosis; Dick, 2001; Boshoff 
and Barry, 2005).  This resistance phenomenon observed with dormant bacteria is 
known as phenotypic, as opposed to genetic, drug resistance.  Hence, one of the central 
goals of modern anti-mycobacterial drug discovery is the identification of compounds 
that can target both actively replicating as well as the non-replicating mycobacteria.  
By employing in vitro screens, it is possible to isolate potent compounds by 
determining their inhibitory/bactericidal concentrations on mycobacteria growing 
under aerobic and hypoxic conditions. 
 
1.4. Symptoms of pulmonary tuberculosis 
Symptoms of active pulmonary tuberculosis include constant coughing, tachycardia, 
chest pain and swollen lymph nodes in the neck (Merck, 2006).  It should be noted 
that, contrary to common belief, bloody sputum is rarely seen in patients.  Fatigue, 
fever, loss of appetite, chills and night sweats can also occur in many patients (Merck, 
2006).  However, symptoms of pulmonary tuberculosis are mild and usually develop 
gradually, thus may easily go unnoticed by patients.  In extrapulmonary tuberculosis, 
the symptoms are more variable and dependent on the type of infected tissue, for 




1.5. Diagnosis of active and latent tuberculosis 
The current gold standard for diagnosis of active tuberculosis is to microscopically 
determine the presence of acid-fact bacilli in patient’s sputum samples following 
isolation of M. tuberculosis in culture (Merck, 2005; Nahid et al., 2006).  Other useful 
tuberculosis diagnostic tools include chest X-ray, tuberculin skin test and IFNγ-based 
assays (Merck, 2005; Nahid et al., 2006). 
 
Until recently, the tuberculin or Mantoux test, where purified protein derivative (PPD) 
of M. tuberculosis is injected intradermally, was the only method available for 
diagnosis of latent tuberculosis (Merck, 2005; Nahid et al., 2006).  However, these 
results can be confounded by prior BCG vaccination and exposure to non-tuberculous 
environmental mycobacteria (Nahid et al., 2006; Pai, 2005).  These problems led to the 
development of γ-interferon based assays (e.g. QuantiFERON-TB Gold test (Cellestis 
Ltd., Australia)) using two region of difference (RD-1) antigens, namely 6-kDa early 
secreted antigenic target (ESAT-6) and 10-kDa culture filtrate protein (CFP-10) 
(Nahid et al., 2006; Pai et al., 2004; Dheda et al., 2005; Pai, 2005; Lalvani, 2003).  
Studies have shown that these tests are more specific, especially in patients who have 
received BCG vaccination, and are proven to be more sensitive than the Mantoux test 
(Nahid et al., 2006; Pai, 2005).  Furthermore, the tuberculin skin test is subjective (i.e. 
the reading is dependent on the attending physician).  Polymerase chain reaction (PCR) 
based diagnostics tests have also been developed, such as Amplicor MTB tests (Roche 
Diagnostic Systems, United States) (Nahid et al., 2006). 
 
Until recently, it is necessary to culture the M. tuberculosis strains isolated from 
patients in order to determine the antibiotic susceptibility patterns to design an 
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appropriate treatment regimen (Nahid et al., 2006).  However, due to the long 
generation time of M. tuberculosis, treatment is often given prior the release of test 
results.  Consequently, numerous kits that rapidly detect drug resistance based on 
molecular beacons and line probes have been designed to accelerate this screening 
process (Nahid et al., 2006; Lin et al., 2004; Morgan et al., 2006). 
 
1.6. Prevention, current treatment, DOTS and drug resistance 
A vaccine based on an attenuated M. bovis strain has been developed and used widely 
for the prevention of tuberculosis.  Drs. Albert Calmette and Camille Guérin passaged 
pathogenic M. bovis several hundred times from 1908-1921 that led to several gene 
deletions and the eventual creation of the bacille Calmette-Guérin (BCG) vaccine.  The 
BCG vaccine was first tested in man in 1921 (Bonah, 2005) and has since been shown 
to confer protection against tuberculosis for as long as 50-60 years after a single dose 
in childhood (Aronson et al., 2004).  However, this protection is variable and is 
possibly due to exposure to M. tuberculosis-like antigens derived from environmental 
mycobacteria (Fine, 1995; Brandt et al., 2002).  For example, in India the vaccine 
offers little or no protection against pulmonary tuberculosis while in the United 
Kingdom it is 70% effective (Fine, 1995; Brandt et al., 2002; Martin, 2006).  
Nevertheless, the BCG vaccine can protect against severe forms of tuberculosis in 
children, such as meningitis and miliary tuberculosis (see Section 1.3.5. 
Extrapulmonary tuberculosis; Zodpey et al., 1996; Powell and Hunt, 2006). 
 
The current WHO-approved treatment for tuberculosis requires a multi-drug therapy 
comprising of: two months treatment with rifampicin, isoniazid, pyrazinamide and 
ethambutol (intensive phase) followed by four months treatment with rifampicin and 
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isoniazid (continuation phase) (WHO, 2003).  In all countries, the WHO recommends 
that the medicines be taken under the supervision of medical professionals to ensure 
that the correct combination of drugs is taken regularly (this is the so-called DOTS 
program: Directly Observed Treatment Short Course).  DOTS was developed to ensure 
patients compliance, thus reducing the emergence of drug resistance.  In addition to 
direct observation of treatment, the success of the DOTS program also depends on 
political/financial support, correct diagnosis and the availability of high quality drugs 
(WHO, 2002). 
 
Since its introduction, the DOTS campaign has reduced non-compliance and disease 
burden of tuberculosis.  In fact, when effectively managed, DOTS results in a high 
cure rate for patients infected with tuberculosis (75% in a recent study in the Russian 
Federation; an additional 14% of patients lost contact; Balabanova et al., 2006).  
Nonetheless, drug resistant tuberculosis is becoming increasingly prevalent.  A recent 
Centers for Disease Control and Prevention (CDC)/WHO tuberculosis survey showed 
that MDR-TB is found in nearly 33% of new cases from the industrialized nations 
between 2000 and 2004 (Centers for Disease Control and Prevention, 2006).  In Asia 
and South America, the percentage of clinical isolates that were MDR-TB was in 
excess of 50%.  WHO estimates that there are around one million cases of MDR-TB 
cases worldwide annually.  Out of the 109 countries surveyed in this study, all have 
cases of MDR-TB (see WHO website: http://www.who.int/mediacentre/ 
news/releases/2006/pr24/en/index.html).  Therefore, it is necessary to develop new 
second-line drugs that are more effective, less expensive and less toxic than the 
currently available ones.  The international community is also making efforts to reduce 
the cost of anti-tuberculosis drugs.  For instance, the Working Group on DOTS-Plus 
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for MDR-TB (the so-called Green Light Committee) that has dramatically reduced 
tuberculosis health care costs (sometimes by as much as 99%) through negotiations 
with the pharmaceutical industry to provide second-line tuberculosis drugs at reduced 
prices (see WHO website: http://www.who.int/tb/dots/dotsplus/management/en/; 
Gupta et al., 2001; Farmer and Kim, 1998; WHO, 2000; Onyebujoh et al., 2005) 
 
1.7. HIV Infection, AIDS and tuberculosis 
As noted previously, one third of the world’s population has latent tuberculosis and 
reactivation of the disease could occur when the patient is old, immunodeficient or 
immunosuppressed (Dye et al., 1999).  Studies have shown that around a third of HIV 
patients are also co-infected with tuberculosis (Onyebujoh et al., 2005; Zumla et al., 
2000).  Moreover, through the DOTS campaign, tuberculosis incidences have been 
decreasing in all countries, except in areas where HIV infection is prevalent (Elzinga et 
al., 2004).  The loss of CD4+ T-lymphocytes in HIV-infected individuals results in 
reactivation of tuberculosis (Chan and Kaufmann, 1994).  Often AIDS patients also 
develop M. avium infections due to the same reason (Inderlied et al., 1993; Ellner et 
al., 1991; Biava et al., 2006).  This presents a major reason for the need to develop 
new tuberculosis drugs, especially since HIV patients have reduced immune capability 
to control mycobacterial infections. 
 
1.8. Essential drug targets in M. tuberculosis 
It is generally believed that an ideal drug target should be an essential gene.  In other 
words, essential genes are those that are required for maintaining the viability of the 
microorganism.  Extensive transposon mutagenesis studies have indicated that one 
third of the M. tuberculosis genes are essential.  These essential genes can be divided 
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into seven gene families, namely proteins/enzymes involved in aminoacyl tRNA 
synthase activities, purine ribonucleotide biosynthesis, polyketide and nonribosomal 
peptide synthesis, fatty acid and mycolic acid biosynthesis, Ser/Thr protein kinase and 
phosphatases, molybdopterin biosynthesis and PE-PGRS repeats (Lamichhane et al., 
2003; Zhang, 2005).  Transposon mutagenesis studies have also identified 
conditionally essential genes (Sassetti et al., 2001) and genes necessary for optimal 
growth under in vitro conditions (Sassetti et al., 2003).  Besides this, gene deletion 
studies have illustrated the essentiality of several mycobacterial genes by 
demonstrating the feasibility of deleting a gene only when an additional copy of the 
gene is introduced into the genome using a plasmid (Zhang, 2005). 
 
However, these results of ‘essentiality’ have to be viewed with caution.  It is 
conceivable that genes that are determined to be non-essential under in vitro conditions 
could well be essential for survival in humans or important for establishing a 
successful infection (Sassetti and Rubin, 2003).  Nevertheless, the data provides us 
with a guide for selecting biological targets for high-throughput screening and drug 
discovery. 
 





















1.9. Chemical genetics as an approach for drug discovery 
In biology, it is possible to study biological systems by manipulating the genetic code 
(genetics) or by modifying the function of a protein using a chemical compound 
(chemical genetics) (Spring, 2005).  ‘Forward’ method of genetics or chemical 
genetics is where the phenotype is selected and the gene/protein responsible for that 
phenotype is elucidated.  Conversely, a ‘reverse’ method involves the manipulation of 
a known gene/protein followed by the analysis of the resulting phenotype (Spring, 
2005).  In antibacterial drug discovery, the phenotype desired is either cellular death or 
inhibition of bacterial replication. 
 
Modern drug discovery using high-throughput screening (HTS) is a reverse chemical 
genetics approach where a library of chemically diverse compounds (usually about 
Table 1.1: Current anti-tuberculosis drug targets with specific examples 
Current Targets Rationale Anti-Tuberculosis Drug Example
Cell Wall 
Synthesis
The thick, waxy mycobacterial cell is an integral part of the bacteria’s defenses against
the hostile environment in the human macrophage. Moreover, to replicate the bacilli are
required to produce more components of the cell wall, such as mycolic acids. Hence,
drugs that target enzymes involved in cell wall synthesis would disrupt the ability of






The replication of DNA is an important part of cellular division. Hence, preventing proper
DNA replication would halt the growth or kill the bacilli. DNA gyrase is also important in




The transcription of the DNA genetic code into mRNA is a necessary part in the
production of proteins. Inhibition of this process would disrupt the intracellular





The purpose of proteins in bacteria, like in other cells, is to maintain the metabolic
homeostasis within the cells. Any disruption of cellular production of proteins would
result in the cellular death or at least inhibition of division. Some of the best tuberculosis







The survival of any bacteria (or cells in general) relies on the production of ATP, the so-
called energy currency of any living entity. Thus, specific disruption of the membrane
potential or electron transport mechanisms in the bacterial cell can inhibit the





1 million) is screened using an enzymatic assay.  Subsequently, compounds capable of 
modulating the activity of the proteins are selected (‘hits’).  Critically, it is necessary 
that a drug target be validated genetically or pharmacologically prior to the HTS.  
Despite the speed and cost-effectiveness of HTS, there is no guarantee that the 
compounds identified can actually penetrate through the cell wall to reach its 
biological target in vivo (Hung and Rubin, 2006).  Moreover, enzymes/proteins used in 
the HTS could have overlapping functions with other enzyme/protein.  Thus, although 
the enzymes/proteins used for HTS are essential, the compound activity exhibited 
under in vitro conditions may not be reflected in vivo (Hung and Rubin, 2006). 
 
Drugs that inhibit novel targets would eliminate the problem of cross-resistance with 
current therapies.  This is especially a problem in infectious disease, such as 
tuberculosis, where multi-drug resistance is fast emerging.  As a drug-discovery 
institute, our goal is to develop new drugs to treat tuberculosis.  To accomplish this, we 
have chosen to use a forward chemical genetics approach because it enables us to 
develop new drugs with a novel mechanism of action.  In other words, we are 
screening a library of compounds against the entire proteome for novel targets, that 









1.10. Technologies available for identification of drug targets 
The identification of the biological target of a compound has several advantages for 
drug development.  Critically, a known drug target would allow scientists to develop 
target-based assays and to facilitate lead optimization by establishing a structure-
activity relationship (SAR).  Moreover, with a known target it would be possible to 
predict potential side effects or toxicity issues. 
 
One method to identify the target of a drug is to generate spontaneous mutants that are 
resistant to the compound of interest and characterize the genomic, proteomic and 
transcriptomics profiles of the mutants in comparison to the parental wild-type strain.  
From this information, the target can be elucidated.  Other more direct methods include 
affinity-chromatography to pull down the protein target or the more traditional method 
of library screening.  It should be noted that sometimes what we identify is not the 
‘target’ but simply a resistance mechanism, e.g. mutating an activating enzyme of a 
pro-drug, or just a protein that binds with the compound (especially in affinity 
chromatography). 
 
1.10.1. Confirmation of drug targets 
The above methodologies and technologies, either used alone or in combination, can 
lead to candidate targets that need to be confirmed with further experiments.  This is a 
crucial part of drug target identification because, positive results from the affinity 
chromatography or protein microarray, could just be a promiscuous binder of the 
compound, rather than a true pharmacological target.  In addition, indirect methods 
such as microarray profiling only gives an indication of the pathway affected by the 
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compound.  It does not pinpoint the gene product that is the actual site of action of the 
compound. 
 
Confirmation of the drug target can be accomplished by over-expressing mutant gene 
in wild-type cells, thereby demonstrating the transferability of observed phenotype.  
This process is also known as complementation.  In addition, gene knock-downs via 
antisense-mediate silencing or gene knockouts via homologous recombination can also 
be used for target confirmation.  However, only the complementation approach is 
practical in mycobacterial drug discovery because gene-silencing techniques are not 




























Figure 1.2: Technologies that can be used to identify the biological target of compounds.  Note that, by definition, 
the proteins/genes identified are only a resistance mechanism or binder of compound but, in some cases, it could be the 
biological target of the compounds.  Confirmation and validation of these results are necessary (for more see in text). 
Approach Used Description Example References
Plasmid or Cosmid 
Library Screening Yes
A library of randomly cut genomic fragments are
expressed in a bacterial population and selected for a
desired phenotype. Plasmid library constructs can
accommodate genomic DNA efficiently between 2kb and
6kb in size, while the cosmid library constructs can contain
up to 45kb of DNA. One would transform either the
mutant library into parental strains or the wild-type library
into mutant cells and selecting for constructs that confer
resistant or sensitivity, respectively.
The putative target of
isoniazid, inhA
Banerjee et al ., 1994;
Vilcheze et al. , 2006
Transposon 
Mutagenesis No
A library of randomly inserted transposon clones, by
definition, targeting non-essential genes can be screened
for a phenotype, such as resistance against a given
compound. 
The inactivation of rdxA 
gene in the Helicobacter 
pylori results in resistance
against the pro-drug
metronidazole.  
Goodwin et al ., 1998
Whole Genome 
Sequencing (WGS) No
This method is based on the central dogma of biology
(gene→mRNA→protein→phenotype). Using drug-
resistant bacteria one can identify the location of the
mutation by sequencing the complete genome. Just a few
years ago, it was necessary to randomly sequence short
segments of DNA that are aligned together ('shot-gun'
approach). It is now possible to sequence the complete
genome of M. tuberculosis  in a few days.  
A successful example of
using this technology to
identify the biological target
of a compound is the
diarylquinoline drug that
targets the ATP synthase 
Andries et al ., 2005
Comparative Genome 
Sequencing (CGS) Yes
This approach is based on the differential hybridization
patterns of fragmented DNA where the profiles between
the parental and mutant are compared and differences
identified. The single nucleotide polymorphisms (SNPs)
are ‘sequenced’ with a DNA chip using a series of








Briefly, total cellular protein extracts are run through an
affinity chromatography column (e.g. latex-based resins)
onto which the compound is immobilized. Following





Raftery et al ., 1980;
Noda et al ., 1982;
Mitchison, 1994;
Brown et al ., 1994;





One protein microarray approach is to directly spot purified 
proteins onto chemically derivatized glass or with
immobilizing antibodies. In eukaryotes, another protein
microarray approach is to spot a collection of plasmid-
based vectors expressing different cDNAs and cover it
with a layer of mammalian cells and transfection reagent.
This would create an array of cells that are over-




et al ., 2001
Transcriptomics Yes
DNA microarrays can identify effects of drug exposure at
the mRNA level. By comparing the mRNA gene
expression profile of the drug with a database, it is
possible to determine if drug acts in the same pathway as
any of the reference drugs. Alternatively, it can also be
determined that a gene-deletion has a similar profile to
compound exposure hence suggesting that gene to be the
target.
A microarray database of
around 400 tuberculosis
drugs has been compiled at
the National Institutes of
Health (Barry, C., USA) with
which we can compare the
profiles of our compounds;
Another example is
dyclonine.
Hughes et al ., 2000;
Boshoff et al ., 2004
Proteomics Yes
Total protein extracts separated on a 2D gel
electrophoresis format will be resolved in both isoelectric
point (pI) and molecular weight (MW) directions; the
identity of spots determined by tandem mass
spectrometry. Cells grown under different conditions,
such as different drug exposure or genetic background,
would have a differential expression of proteins or a
change in protein mobility.





methionine based on the
identification of 1500
different spots. 
Towbin et al ., 2003
Lipidomics Yes
Similar to microarray profiling, this technique needs a
database of metabolite profiles treated with a spectrum of
drugs that can be used for comparison with the profile of






































1.10.2. Validation of drug targets 
In antibacterial drug discovery, validation of a drug target involves the understanding 
of the protein’s function in the microbe and how by the inhibition of the protein or 
alteration of its function could lead to the death or inhibition of the pathogenic 
organism.  In other words, we have to prove that the target is essential for the 
survival/infectivity of the microorganism or at least is important in some stage of 
disease progression (Stockwell, 2000).  This is often the bottleneck in the drug 
discovery process, especially for new drug targets where very little is known about its 
function (Stockwell, 2000). 
 
1.11. Goals of Tuberculosis Drug Research and Discovery 
In summary, there is a great need to develop drugs for tuberculosis and ideally these 
new drugs have to inhibit novel biological targets to avoid cross-resistance with 
current therapies.  The best drug targets should be essential in both active and dormant 
phases of M. tuberculosis infection so that a single drug would eradicate both bacterial 
populations.   
 
Ultimately, according to the Scientific Blueprint for Tuberculosis Drug Development 
(Global Alliance for TB Drug Development) any new drug would have to: (1) improve 
the current tuberculosis treatment by shortening the length of therapy, (2) be more 
effective against MDR-TB and (3) in light of the fact that two billion people are 
latently infected with M. tuberculosis, the drugs need to have efficacy against latent 




In this study, we aim to isolate and characterize M. bovis BCG and M. smegmatis drug-
resistant mutants to Compound X and Compound Y.  Using these drug-resistant 
mutants, we intend to identify the drug target of Compound X and Compound Y using 





























2. Materials and Methods 
 
2.1. Bacterial Strains, Growth Media, Compounds and Drugs 
2.1.1. Bacterial Strains 
The slow-growing Mycobacterium bovis BCG (ATCC 35734; M. bovis BCG will be 
known as BCG) and fast-growing M. smegmatis (mc2155) were used in the 
experiments.  Escherichia coli TOP10 cells (Invitrogen, USA) were used in cloning 
experiments.  
 
2.1.2. Bacterial Culture Media 
Luria-Bertani (LB) broth and LB agar plates: Both media were used to culture E. coli 
cells.  LB (Becton Dickinson, USA) broth was filter sterilized and stored at 37°C until 
use.  LB Agar (Becton Dickinson, USA) was autoclaved and an appropriate amount of 
antibiotic was added immediately before the plates were prepared.  After the plates set, 
they were stored at 4°C until required.  When required, LB broth and LB agar plates 
was supplemented with 50µg/ml kanamycin (Sigma, USA), 150 µg/ml hygromycin 
(Roche, Switzerland) or 100 µg/ml of ampicillin (Sigma, USA). 
 
Middlebrook 7H9 broth: Mycobacterial cultures were grown using this liquid media.  
Middlebrook 7H9 was prepared according to manufacturer’s protocols (Becton 
Dickinson, USA) and supplemented with 0.2% glycerol, 0.05% Tween-80 and 10% 
(v/v) Albumin-Dextrose-Saline (ADS: 950ml dH20, 8.1g NaCl, 50g Bovine Serum 
Albumin Fraction V, 20g D-dextrose).  The complete medium was filter sterilized and 
stored at 37°C until use.  When required, Middlebrook 7H9 broth were supplemented 
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with 25µg/ml kanamycin or 50 µg/ml hygromycin for antibiotic selection.  Tween-80 
was added in the media in order to decrease cellular clumping. 
 
Middlebrook 7H10 agar plates: This solid media was used to isolated colonies of 
mycobacteria.  Middlebrook 7H10 was prepared according to manufacturer’s protocols 
and autoclaved.  After sterilization, the media was supplemented with 0.5% glycerol, 
0.05% Tween-80 and 10% (v/v) oleic acid-dextrose-albumin-catalase enrichment 
(OADC; Becton Dickinson, USA).  When required, Middlebrook 7H10 agar plates 
were supplemented with either 25µg/ml kanamycin or 50 µg/ml hygromycin for 
antibiotic selection. 
 
2.1.3. Glycerol stock of bacteria 
E. coli: Glycerol stocks of overnight cultures were prepared by resuspending in LB 
broth containing 15% glycerol (v/v) and stored as 1ml aliquots at -80ºC.   
BCG and M. smegmatis: Glycerol stocks of cultures were prepared by resuspending in 
Middlebrook 7H9 broth containing 15% glycerol (v/v) and stored as 1ml aliquots at -
80ºC.   
 
2.1.4. Compounds 
All compounds were prepared as 5mM stocks in 90% DMSO and stored at 4°C until 
further use.   
 
2.1.5. Drugs 
Phosphomycin, imipenem, gatifloxacin, ethambutol, amikacin, ciprofloxacin, 
kanamycin, ofloxacin, vancomycin, ceftriaxone, azithromycin, gentamicin, ampicillin, 
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tetracycline, trimethoprim, moxifloxacin, cycloserine, sulfamethoxazole, rifampicin, 
streptomycin, isoniazid, rifabutin and linezolid stocks were prepared as 5mM stocks in 
90% dimethyl sulfoxide (DMSO) and stored at 4°C until further use.  These drugs 
were obtained from Sigma (USA) and Merck (USA). 
 
2.2. Isolation and characterization of compound resistant mutants 
2.2.1. MIC50 and MBC90 determination  
The MIC50 (Minimum Inhibitory Concentration50) is defined as the minimum 
concentration of compound at which 50% of mycobacterial growth is inhibited.  100µl 
of Middlebrook 7H9 was aliquoted into each well of a flat-bottom 96-well plate.  A 
compound solution (in Middlebrook 7H9) at four-times the highest concentration 
required was prepared and aliquoted into the top wells of a 96-well plate followed by a 
two-fold serial dilution (for concentrations used see Table 2.1).  Each of the wells were 
seeded with mycobacterial cells at a final optical density of 0.02 for BCG and 0.01 for 
M. smegmatis.  The optical density was determined at 600nm (OD600; 
SPECTRAmaxM2, Molecular Devices, USA) after 5 days of incubation for BCG and 
2 days for M. smegmatis at 37ºC.  The MIC50 values were calculated using the 
statistical software Prism (GraphPad, USA), where 100% growth is defined according 
to the average of the wells containing no compound.  All compounds were tested in 
duplication in three independent trials. 
 
The minimum bactericidal concentration 90 (MBC90) is the lowest concentration of the 
compound that results in the killing of 90% of bacilli from the starting inoculum.  This 
was calculated by determining the colony-forming units (CFUs) at day 0 and day 5 
following compound treatment on Middlebrook 7H10 agar plates.  Since the MBC90 is 
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higher than the MIC50, we plated out the culture from the wells with concentrations 
higher than the MIC50 (usually up to 4 wells above the MIC50).  The CFUs of the no-
drug control (using both initial inoculum at day 0 and the cells after 5 days of 
incubation) were also determined. 
 
2.2.2. Isolation of spontaneous compound-resistant mutants (mutation 
frequency determination) 
Based on the MIC50 assay results, mutants resistant to CpdX were isolated.  400ml of 
wild-type BCG were grown to an optical density of 0.4.  Following centrifugation at 
3,000rpm for 10 minutes, the cell pellet was resuspended in 1ml of fresh Middlebrook 
7H9 broth.  100µl of concentrated culture was plated onto Middlebrook 7H10 agar 
plates containing five and ten times MIC90 concentration of the compound under 
investigation (in duplicates).  100-fold diluted cultures were also plated out on five and 
ten times MIC90 concentration on Middlebrook 7H10 agar plates in duplicates.  In 
order to estimate the bacterial CFUs in the original culture, 100µl of 106, 107 and 108-
fold diluted culture were plated onto Middlebrook 7H10 agar plates without drugs.  
The agar plates were incubated at 37°C for between 3 to 5 weeks prior to determining 
the CFUs counts and isolation of spontaneous resistant mutants.  Note that the protocol 
used for M. smegmatis was similar with the only difference being that the mutants 
were isolated following 3-5 days of incubation at 37°C.  In addition, the mutation 
frequency of CpdX and CpdY for BCG, and CpdY for M. smegmatis were also 
determined in the same experiment.  We determined the mutation frequency of 
rifampicin as a positive control. 
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Compound-resistant mutants were colony purified by plating out on fresh Middlebrook 
7H10 agar plates.  From this, single colonies were isolated and grown in 2-3ml of 
drug-free Middlebrook 7H9 broth.  Following growth, 0.5ml of the culture was 
transferred into 5ml of fresh Middlebrook 7H9 broth containing the appropriate 
concentration of drug with which each mutant was originally isolated.  Following 
growth to an OD600 of 0.4 to 0.8, the bacterial cultures were spun down (3,000 rpm for 
10 minutes), resuspended in fresh compound-free Middlebrook 7H9 broth with 15% 
glycerol and stored in aliquots at -80°C. 
 
2.2.3. Selection of drugs to use in cross-resistance studies 
The MIC50 of phosphomycin, imipenem, gatifloxacin, ethambutol, amikacin, 
ciprofloxacin, kanamycin, ofloxacin, vancomycin, ceftriaxone, azithromycin, 
gentamicin, ampicillin, tetracycline, trimethoprim, moxifloxacin, cycloserine, 
sulfamethoxazole, rifampicin, streptomycin, isoniazid, rifabutin and linezolid were 
determined in BCG and M. smegmatis according to protocols outlined in Section 2.2.1. 
(MIC50 and MBC90 determination) starting at 40µM for all drugs.   
 
2.3. Molecular Biology 
2.3.1. Polymerase Chain Reaction (PCR) 
PCR was used to amplify the mutant and wild-type corA gene to facilitate cloning into 
the TOPO vector (pCR2.1-TOPO; Invitrogen) as outlined in the next section.  Briefly, 
a PCR mixture (total volume 30µl), comprising of ~200ng of template DNA was 
mixed with Pfu Ultra HotStart mix (15µl; Stratagene; USA), 10mM primers (0.5µl) 
and made up to 30µl with dH2O.  Amplification conditions were as follows: hot start of 
5min at 95°C; 25 cycles of denaturing (95°C for 30 s), annealing (58°C for 15 s), and 
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extension (72°C for 30s); and a final extension of 10min at 72°C was used for 
sequencing, expression and knock-out studies (PCR machine: Biometra T3000, 























Table 2.1: List of primers used for sequencing and expression studies 
Primer Name Primer Sequence
H37Rv CorA Seq.fw1 5'-ATCCACCGCGATCGGAGGTT-3'
H37Rv CorA Seq.rv1 5'-TGTTCGCCGACGCGAAGCTA-3'
H37Rv CorA Seq.fw2 5'-CGGCGAACACGGCGGGTTAT-3'
H37Rv CorA Seq.rv2 5'-CCATGAGATTGGTCACCTCG-3'
Msmeg CorA Seq.fw1 5'-AACATGGCGAAGTTCCGGGC-3'
Msmeg CorA Seq.rv1 5'-TCCCTCCTGAGGCTCTAGAG-3'
Msmeg CorA Seq.fw2 5'-GATTCCTCGCCGTCGATCCT-3'
Msmeg CorA Seq.rv2 5'-GATCGGTGACATCGAGGTAG-3'
Msmeg CorA-like Seq.fw1 5'-TTGACTCACGGCATGGCGCAGG-3'
Msmeg CorA-like Seq.rv1 5'-CTACAGCCAATCGCGGCGCTTG-3'
Msmeg CorA-like Seq.fw2 5'-TCGGCGTTCGTGTTGCCGCACG-3'





H37Rv CorA Exp.fw 5'-TTGGCCTCCAGCAGGTCACT-3'
H37Rv CorA Exp.rv 5'-ACCGCCAGACTTGCCGTCTT-3'
Msmeg CorA Exp.fw 5'-GCCGAACGTCTTGAACAAC-3'




2.3.2. TOPO cloning 
The TOPO-cloning solution was prepared as follows: 4µl of fresh PCR product, 1µl of 
sterile water, 1µl of the salt solution (1.2M NaCl, 0.06M MgCl2) and 1µl of the TOPO 
was incubated at room temperature for 5minutes.  The entire solution was transformed 
into chemically competent E. coli Top10 cells (Invitrogen, USA). 
 
2.3.3. Transformation of E. coli and mycobacteria 
DNA was mixed gently with a thawed aliquot of chemically competent E. coli Top10 
cells and incubated on ice for 30 minutes.  The competent cells were heat shocked at 
42ºC for 1 minute and chilled on ice.  500µl of LB was added to the cells followed by 
incubation in a shaker for 60-90 minutes at 37ºC to allow for expression of antibiotic 
resistance.  The cells were centrifuged briefly and the LB decanted off leaving 
approximately 100µl.  The cells were resuspended and spread onto LB Agar plates 
containing kanamycin and incubated overnight at 37°C.  For the TOPO clones, 40µL 
of Xgal reagent was added onto the plates prior to plating cells to facilitate the 
selection of recombinant colonies, which will appear white due to the insertion of the 
DNA into the lacZ gene (lacZ gene codes for β-galactosidase that can break down 
Xgal to a blue product).  A single white colony was used to inoculate 3ml of LB broth 
and plasmids were purified following protocols in Section 2.3.9. followed by 
restriction endonuclease digestion (Section 2.3.4.) and sequencing (Section 2.3.12.). 
 
For BCG, electrotransformation was used to introduce foreign DNA.  100ml of mid-
log phase cells were made electrocompetent by washing the cells with 10% glycerol 
three times and resuspending in 1ml of 10% glycerol.  200µl of cells was mixed with 
the DNA in a 0.2cm cuvette and incubated for 5-10minutes at room temperature.  
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Following electroporation (BioRad Gene Pulser, settings: 2500mV, 1000Ω, 25µF), 
1ml of Middlebrook 7H9 media was added to the cells and incubated overnight at 37ºC 
in sterile tubes to allow expression of antibiotic resistance gene. 
 
2.3.4. Restriction Enzyme Digestion 
Analytical restriction enzyme digestion was used to screen for recombinant plasmids 
containing the DNA of interest.  The digestion reaction mixture consist of ~200ng of 
plasmid DNA, 1 unit restriction enzyme, appropriate buffer and made up to a final 
volume of 10µl with dH2O.  The whole mixture was incubated at the appropriate 
temperature for 30-120 minutes  and separated by agarose gel electrophoresis (Section 
2.3.5. Agarose Gel Electrophoresis).  The restriction enzymes used were supplied by 
Invitrogen, New England BioLabs or Roche.   
 
2.3.5. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate the DNA fragments of different sizes.  
A 1% agarose gel was used unless otherwise indicated.  The appropriate amount of 
agarose (GibcoBRL) was added to the 1xTris-Acetate EDTA buffer (1xTAE Buffer; 
40mM Tris, 1.4% (v/v) glacial acetic acid, 1mM EDTA) and microwave-heated until 
the agarose had completely dissolved.  Ethidium bromide (around 1µl of 10mg/ml 
stock; GibcoBRL) was added and the gel poured into a casting tray and left to set.  The 
gel was placed in an electrophoresis tank (BioRad) and submerged in 1xTAE buffer.  
Each sample was mixed with 6xDNA loading dye (0.03% xylene cyanol FF, 0.03% 
bromophenol blue, 60% glycerol, 1% sodium dodecyl sulfate (SDS), 100mM EDTA 
(pH 7.6)) and 3-5 µl of molecular mass standard 1kb plus ladder (GibcoBRL; 100µL 
H2O, 25µl loading dye, 375µl 20mM NaCl) and loaded in adjacent wells.  
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Electrophoresis was performed at 120V for approximately 30minutes.  The gel was 
exposed to UV light (Gene Genius, Syngene, United Kingdom) to visualize the DNA 
fragments. 
 
2.3.6. Purification of digested plasmid DNA from agarose gels 
1-2µg of plasmid DNA was digested with restriction enzymes and separated on a 1% 
(w/v) agarose gel for approximately 30minutes at 180V.  With the aid of UV light, the 
gel bands that contained the vector and insert DNA were excised and purified from the 
agarose gel using the QIAquick gel extraction kit (Qiagen, USA).  The DNA was 
eluted with TE buffer. 
 
2.3.7. Dephosphorylation of DNA 
Digested vector DNA was treated with 1U of Shrimp alkaline phosphatase (SAP) for 
15 minutes to remove 5’ phosphates.  This would prevent self-ligation of the vector.  
The vector DNA was purified using the QIAquick gel extraction kit (Qiagen, USA) 
according to the manufacturer’s instructions. 
 
2.3.8. Ligation of DNA fragments 
Ligation was carried according to manufacturer’s instructions (Roche Rapid Ligation 
Kit) with 100ng of vector DNA and insert DNA at 3-5 molar excess.  The ligation 
mixture was incubated at room temperature for 5 minutes prior to transformation into 
competent E. coli TOP10 cells (Section 2.3.3. Transformation of Plasmid DNA). 
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2.3.9. Small scale preparation of plasmid DNA 
Chemically competent E. coli transformed with plasmids were inoculated in 3ml of LB 
containing 50µg/ml of ampicillin or 150µg/ml of hygromycin and cultured at 37oC 
overnight.  The plasmid DNA was purified according to the manufacturer’s protocol 
(Roche High Pure Plasmid Isolation Kit Handbook).  The DNA was eluted with TE 
(Tris-EDTA buffer: 10mM Tris HCl pH8.0, 1mM EDTA, 50µg/ml RNAseA (Roche)) 
buffer and stored at -20ºC until further use. 
 
2.3.10. Large scale preparation of plasmid DNA 
100ml of LB supplemented with 50µg/ml of ampicillin or 150µg/ml of hygromycin 
was inoculated with either a bacterial glycerol stock or a small starter culture of 2-5ml 
LB (with 50ug/ml of ampicillin).  The bacteria were grown for 14 hours overnight on a 
shaker-incubator at 37ºC.  Plasmid DNA was purified according to the manufacturer’s 
instructions (Qiagen, USA).  The plasmid DNA was resuspended in TE and stored at -
20ºC until use. 
 
2.3.11. Sequencing 
Plasmids and gel-purified PCR products were sequenced using am ABI PRISM 3100 
capillary sequencer (Applied Biosystems, USA) at Research BioLabs Technologies Pte 
Ltd (Singapore).  For sequencing inserts in the TOPO vector the T3 forward and T7 
reverse primers were used (for sequences of the primers see Invitrogen website; 
available at www.invitrogen.com).  For sequencing PCR products, the primers used in 
amplification were used in addition to internal primers.  Note that since the sequencing 
reaction can only accurately read out approximately 600bp, hence to obtain the 
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sequence of the full-length corA gene internal primers were required (H37Rv corA 
seq.fw2 and rv2). 
 
2.4. Identification of drug target 
2.4.1. Comparative Genome Sequencing 
Comparative genome sequencing is a hybridization-based sequencing method 
(NimbleGen, USA).  For more information please visit: www.nimblegen.com.  We 
provided NimbleGen with phenol:chloroform purified genomic DNA comparative 
hybridization studies. 
 
2.4.1.1. Genomic DNA preparation 
100ml of culture (OD600 0.4-0.8) was split into five tubes and spun down in a tabletop 
centrifuge and resuspended in 1ml of GTE solution (25mM Tris-HCl pH8.0, 10mM 
EDTA, 50mM glucose).  In a 2ml microfuge tube, the cells were resuspended in 450µl 
of GTE solution with 50µl of 10mg/ml lysozyme solution (Sigma, USA).  Following 
an overnight incubation at 37ºC, 100µl of 10% (w/v) SDS and 50µl of 10mg/ml 
proteinase K was added and incubated at 55ºC for 20-40 minutes.  Following addition 
of 200ul of 5M NaCl, 160µl of preheated cetyltrimethylammonium bromide solution 
(CTAB solution: 4.1g NaCl, 10g CTAB in 90ml dH2O) was added to the mixture and 
incubated at 65ºC for 10 minutes.  Phase separation was achieved with equal volume 
of chloroform:isoamyl alcohol (24:1) coupled to centrifugation for 5 minutes (repeated 
twice using the previous aqueous phase).  Equal volume of isopropanol was used to 
precipitate the genomic DNA and the pellet following centrifugation was washed with 
70% ethanol.  The air-dried, ethanol-washed DNA pellet was resuspended in 1xTE and 
stored at 4ºC until required.  
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2.4.1.2. Determination of DNA concentration and purity 
A NanoDrop ND-1000 Sprectrophotometer (NanoDrop Technologies, USA) was used 
to determine the genomic DNA concentration.  The A260/280 ratio was used to 
determine the purity of the DNA preparation, where a ratio of 1.8 indicates a high 
purity DNA preparation devoid of proteins, aromatic compounds and RNA 
contamination. 
 
2.4.2. 2D gel electrophoresis 
2.4.2.1. Sample preparation 
Whole-cell extracts were prepared from BCG by harvesting 100ml of culture or wild-
type and mutant strains grown for 3 days with or without CpdX drug pressure (at either 
0.6µM or 1.2µM).  Cultures were pelleted by centrifugation at 3000rpm for 15minutes.  
Cell pellets were washed three times with water containing 0.05% (v/v) Tween 80.  
Mycobacteria were resuspended in lysis buffer, containing 25mM Tris pH8, 0.1mM 
EDTA, 5% glycerol, 1% Triton-X 100, 1mM PMSF and 50mM dithiothreitol (DTT), 
and lysed by bead disruption in a ribolyser (Eppendorf, Germany)  The debris in the 
lysate was spun down and the supernatant removed.  The protein concentration of each 
sample was estimated using the BioRad Protein Assay (USA). 
 
2.4.2.2. Electrophoresis 
Isoelectric focusing sample loading buffer (8M urea, 2% (w/v) CHAPS, trace amount 
of bromophenol blue) was added to the samples and each separated using pH 4-7 18cm 
IPG strips (Amersham Bioscience) in the first dimension.  Total protein (100µg made 
up to 350µl with sample loading buffer and 1.4µl 0.5M Tris-(2-
carboxyethyl)phosphine hydrochloride (TCEP), 1.75µl IPG buffer) was loaded at the 
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cathode end and proteins focused as follows using EtthanTM IPGphor (Amersham 
Bioscience): 30V for 12h, 500V for 1h, 1000V for 1h, 8000V for 8h (total of 
60,000Vh).  Second-dimension electrophoresis was carried out using 18x18cm format, 
1·5mm thick, 12% polyacrylamide gels (50ml: 16.5ml dH2O, 20ml 30% acrylamide 
mix, 12.5ml 1.5M Tris pH8.8, 0.5ml 10% SDS, 0.5ml 10% ammonium persulfate, 
0.02ml TEMED).  IPG strips were equilibrated with prior to running on the second 
dimension using equilibration buffer (200ml: 6.7ml 1.5M Tris-HCl pH8.8, 6M urea, 
69ml glycerol, 4g SDS and bromophenol blue) with 10mg/ml DTT for 15 minutes and 
equilibration buffer with 25mg/ml iodoacetamide for 20 minutes.  Strips were then 
overlaid onto the second-dimension gels and sealed with 0.5% (w/v) agarose in cathode 
buffer (TGS Buffer, BioRad, USA), containing a trace amount of bromophenol blue. 
 
2.4.2.3. Silver staining 
For protein spot comparisons, gels were silver stained.  Firstly, gels were immersed in 
fixing solution, comprising of 50% (v/v) methanol and 5% (v/v) acetic acid, for at least 
1 hour.  This was followed by successive incubations in 0.02% (w/v) sodium 
thiosulfate for 2min, 0.1% chilled silver nitrate for 40min and 0.014% formaldehyde 
plus 2% sodium carbonate.  The reaction was stopped with 5% (v/v) acetic acid.  Gel 
images were digitized by scanning on a flat-bed scanner (ScanJet2400, Hewlett 
Packard, USA) at a resolution of 300dpi. 
 
2.4.2.4. Spot identification 
Protein spots of interest were excised and send for identification at the Biopolis Shared 
Facility (Singapore) using Q-STAR (LC-MS) in order to concentrate the protein prior 
to mass spectrometry. 
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2.4.2.5. Database searching 
Tandem mass spectra were extracted, charge state deconvoluted and deisotoped by 
ABI Analyst version 1.4.  All MS/MS samples were analyzed using Mascot (Matrix 
Science, London, UK; version 2.1.03) and X! Tandem (www.thegpm.org; version 
2006.04.01.2). X! Tandem was set up to search a subset of the uniprot_20060725 
database also assuming trypsin.  Mascot was set up to search the uniprot_20060725 
database (selected for M. tuberculosis complex, unknown version, 9837 entries) 
assuming the digestion enzyme trypsin.  Mascot and X! Tandem were searched with a 
fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 200 PPM. 
Oxidation of methionine and iodoacetamide derivative of cysteine were specified in 
Mascot and X! Tandem as variable modifications.  
 
2.4.2.6. Criteria for protein identification 
Scaffold (version Scaffold-01_06_03, Proteome Software Inc., USA) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 0.0% probability as specified by 
the Peptide Prophet algorithm (Keller et al., 2002).  Protein identifications were 
accepted if they could be established at greater than 99.0% probability and contained at 
least 2 identified peptides.  Protein probabilities were assigned by the Protein Prophet 
algorithm (Nesvizhskii, 2003).  Proteins that contained similar peptides and could not 





Sequences of corA in M. tuberculosis H37Rv, M. tuberculosis CDC1551, 
M. smegmatis mc2155, M. bovis, M. leprae, M. paratuberculosis, M. flavescens and M 
tuberculosis strain C were aligned using VectorNTI to determine their homology to 






























3.1. Anti-mycobacterial activity of Compound X and Compound Y 
CpdX was selected from a library of 8,800 synthetic compounds following a growth 
inhibition screen on actively replicating BCG.  CpdY was selected based on structural 
similarities to CpdX (personal communication, Vasan Sambandamurthy, NITD, 
Singapore).   
 
The inhibitory and bactericidal activity of the two structurally-related chemical 
compounds, CpdX and CpdY, were determined.  They both have good inhibitory 
activity on slow-growing mycobacterial species grown under aerobic conditions.  
CpdX has excellent bactericidal activity against BCG grown under aerobic conditions.  
However, CpdX has weak activity against M. smegmatis (over 25µM), while CpdY has 












Table 3.1: Anti-mycobacterial properties of CpdX and CpdY against wild-type M. bovis BCG 
and M. smegmatis.  This table summarized the basic biological properties of the two compounds 
against M. bovis BCG and M. smegmatis.  (ND denotes not done and all MIC50 and MBC90 values are 
expressed in µM) 
M. bovis  BCG M. smegmatis
Compound X 0.62-1.73 >25 <2.5
Compound Y 0.36 1.47 ND
Compound
MIC50
MBC90 M. bovis  BCG
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3.2. Isolation of spontaneous resistant mutants to Compound X and 
Compound Y  in M. bovis BCG and M. smegmatis  
Mutation frequency studies 1) can hint at whether the bacteria can quickly acquire 
genetic resistance, if used as a monotherapy and 2) allow for the isolation of resistant 
mutants that can be genetically analyzed so as to ascertain the mutation that confers 
resistance and possibly establish the biological target of these compounds.  The 
frequency of appearance of spontaneous resistant mutants for both compounds in BCG 
was ~10-8 at 10 times MIC90, and for CpdY in M. smegmatis it was around 10-8 (see 
Table 3.2)  This is comparable with rifampicin, where spontaneous resistant mutants 
arise at a frequency of 10-8, and significantly lower than that of isoniazid (10-6) (data 
not shown).  The mutation frequency experiment was not carried out using CpdX in 
M. smegmatis because the MIC50 value for the CpdX was more than 25µM and hence 
would require the use of very large amounts of the compound on M. smegmatis.  The 
level of resistance acquired by the spontaneous resistant mutants are determined using 








Table 3.2: Mutation frequency experiment for CpdX and cpdY in wild-type M. bovis BCG and 
M. smegmatis.  This table summarizes the results of the mutation frequency experiments.  (ND denotes not 
done) 
 
Name Pressure 1 2 Average
M. bovis  BCG Compound X 10 × MIC50 1.5 × 10-8 1.1 × 10-8 1.3 × 10-8
M. bovis  BCG Compound Y 10 × MIC50 4.9 × 10-9 ND ND




3.3. Characterization of M. bovis BCG and M. smegmatis compound-resistant 
mutants  
CpdX-resistant BCG mutants were isolated and the level of resistance of each mutant 
strain were determined via turbidimetry-based growth assay.  Moreover, to eliminate 
the possibility that the bacteria are resistant because of a mutation in one of the major 
transporter protein resulting in impermeability to drugs or mutation in a drug efflux 
system, we tested the mutants against a selection of frontline anti-tuberculosis drugs.  
Hypothetically, mutations in a transporter could either decrease the entry of drug or 
increase the efflux of drug out of the cell (De Rossi et al., 2006; specifically for M. 
tuberculosis:  a transporter of the major facilitator superfamily - De Rossi et al., 2002; 
a transporter of the small multi-drug resistance family - De Rossi et al., 1998).  In both 
cases, this leads to a decrease in the accumulation of the drug within the bacterial cell, 
thereby contributing to the increase in MIC50 value of mutants.   
 
In order to decide which drugs are to be included in this panel, we tested 23 anti-
bacterial drugs against wild-type BCG (see Table 3.3).  From these, we chose 
streptomycin, moxifloxacin, rifampicin and ethambutol, which targets the protein 
synthesis, DNA coil relaxation, transcription and cell wall synthesis, respectively. 
 
Colony purified CpdX-resistant BCG strains showed 6 to 14 times increase in the 
MIC50 values as compared to wild-type BCG (see Table 3.4).  Similarly, the colony 
purified CpdY-resistant BCG mutants showed between 2 to 3 times increase in MIC50 
value as compared to wild-type BCG.  The MIC50 values only increased with the 




















the MIC50  value for ethambutol, moxifloxacin, streptomycin and rifampicin remained 
comparable with the wild-type strain.  Similarly, although colony-purified 
M. smegmatis CpdY-resistant strains showed MIC50 values of over 40µM for CpdY, 
the mutant strains remained sensitive to the other four drugs.   
 
The data from this set of experiments suggest that these mutants have acquired specific 
resistance to the test compound through random mutations, presumably in its 
biological target.  Hence, after successfully isolating and characterizing drug-resistant 
Table 3.3: The MIC50 values for 23 standard drugs against wild-type M. bovis BCG and M. smegmatis. 
(ND denotes not done and all MIC50 values are expressed in µM) 
Drug M. bovis  BCG MIC50 M. smeg  MIC50 Bacterial Target
Amikacin <0.156 0.79 30S ribosomal subunit
Gentamicin 1.26 0.70 30S ribosomal subunit
Imipenem >20 >40 30S ribosomal subunit
Kanamycin 0.51 0.87 30S ribosomal subunit
Streptomycin <0.156 <0.3 30S ribosomal subunit
Ciprofloxacin 0.21 0.51 DNA gyrase
Gatifloxacin <0.156 <0.3 DNA gyrase
Moxifloxacin <0.156 <0.3 DNA gyrase
Ofloxacin >20 >40 DNA gyrase
Rifabutin <0.156 0.34 DNA-dependent RNA polymerase
Rifampicin <0.156 6.11 DNA-dependent RNA polymerase
Sulfamethoxazole 1.64 >40 Dihydrofolate reductase
Trimethoprim >20 19.61 Dihydrofolate reductase
Ampicillin >20 >40 Cell wall synthesis (Penicillins)
Azithromycin 0.47 2.43 Protein synthesis (Macrolides)
Ceftriaxone 6.56 >40 Cell wall synthesis (Cephalosporins)
Cycloserine >20 >40 Cell wall synthesis
Ethambutol 2.51 1.07 Cell wall synthesis
Isoniazid >20 >40 Cell wall synthesis
Linezolid >20 0.84 Protein synthesis (Oxazolidinones)
Phosphomycin >20 >40 Enolpyruvate transferase
Tetracycline 7.52 2.31 Translation (Tetracyclines)







mutants, we proceeded to characterize these mutants using genetic and proteomic 






















Table 3.4: Cross-resistance study of CpdX and CpdY-resistant M. bovis BCG and M. smegmatis
mutants.  S denotes susceptibility to drug and R means resistance to drug; Susceptibility is defined as 
having an MIC50 value very similar to wild-type with a very slight variation. 
Compound X Ethambutol Moxifloxacin Streptomycin Rifampicin 
wild-type 1.73 2.28 0.070 0.075 0.0062
1 23.24 S S S R (0.031)
2 19.69 S S S S
6 16.51 S S S S
7 10.44 S S S S
10 15.60 S S S S
13 20.79 S S S S
Compound Y Ethambutol Moxifloxacin Streptomycin Rifampicin 
wild-type 0.36 2.28 0.070 0.075 0.0062
1 0.625-1.25 S S S S
2 1.07 S S S S
Compound Y Ethambutol Moxifloxacin Streptomycin Rifabutin 
wild-type 1.47 1.00 0.16 0.19 0.65
1 >40 S S S S
2 >40 S S S S
4 >40 S S S S
9 >40 S S S S
M. bovis  BCG 
Strains
Minimum Inhibitory Concentration50 (MIC50 in µM)
Minimum Inhibitory Concentration50 (MIC50 in µM)M. smegmatis  
Strains
Minimum Inhibitory Concentration50 (MIC50 in µM)M. bovis  BCG 
Strains
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3.4. Sequencing of M. bovis BCG and M. smegmatis mutant 
Without any prior indication or the knowledge of the biological target, the most 
promising option for target identification is to sequence the whole genome of several 
mutant strains to determine the SNP(s) that result in resistance.  The open reading 
frame (ORF) in which the SNP(s) are located would very likely be the biological target 
of the compound or at the very least predicts the mechanism of resistance.  The 
feasibility of this novel whole genome sequencing approach was elegantly 
demonstrated by the identification of ATP synthase to be the target for a 
diarylquinoline drug – designated R207910 (Andries et al., 2005).   
 
As an alternative approach to whole genome sequencing, we chose to utilize a chip-
based sequencing technology marketed by NimbleGen Inc (United States).  One 
CpdX-resistant mutant of BCG (designated strain 10) was sent for comparative 
genome sequencing (CGS).  A single SNP (Single Nucleotide Polymorphism) was 
present in BCG1299c (Rv1239c) open reading frame that codes for a putative 
magnesium and cobalt transport protein (CorA).  The genetic mutation resulted in a 
non-synonymous substitution of alanine with serine at amino-acid position 317.  
CpdY-resistant mutants were not sent for comparative genome sequencing, however 
given the structural similarity between CpdX and CpdY, we believed that the corA 
gene in CpdY resistant mutants should have mutations in the corA gene as well (this 
was true for BCG mutants) 
 
With this data, we designed primers to amplify and sequence the corA gene from 
CpdX and CpdY-resistant mutants of BCG.  In all strains, except one BCG mutant, we 
found SNPs in the corA gene.  Four individual types of genetic mutations were 
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mapped to the corA gene that resulted in a G299S, M300V, A313S and A317S 
substitution at the protein level, in both CpdX and CpdY-resistant mutants.  The 
location of these amino acids in the folded protein is unknown and cannot be compared 
with the recently crystallized CorA protein from Thermotoga maritima, because the 
corA gene of T. maritima shares less than 30% homology with the M. tuberculosis 
corA (Eshaghi et al., 2006; Maguire, 2006; Lunin et al., 2006).  No SNPs in the corA 
gene were isolated in strain 7 of CpdX-resistant BCG mutant.  This result was 
confirmed with two independent PCR and sequencing reactions.  Thus, it would be 
interesting to sequence this particular strain via comparative genome sequencing to 
isolate another SNP that is also capable of conferring resistance to CpdX.  
Unexpectedly, the M. smegmatis CpdY-resistant mutants had no mutations in corA as 
well as the corA-like gene (as annotated by The Institute for Genomic Research, 
TIGR), thus suggesting another resistance determinant. 
 
In summary, a mutation within CorA at specific amino acid residues in BCG is able to 
confer resistance to CpdX and CpdY.  However, in M. smegmatis, no mutation was 

































































































































































































































































































































































































































































































































3.5. Expression of corA in M. bovis BCG  
As noted in the introduction, one of the methods for determining if a gene is the 
biological target of a compound is to express the mutant copy of that gene in wild-type 
bacteria and determine if the resistance is transferred into the wild-type bacteria.  In 
addition, the expression of the wild-type gene in mutant bacteria will allow us to 
determine if the mutant phenotype is dominant. 
 
To this goal, we cloned separately the mutant and wild-type copy of corA gene along 
with a 500bp upstream region predicted to contain the promoter into the pMV306 
Table 3.5: CorA mutations found in all the sequenced CpdX and CpdY-resistant M. bovis BCG and 
M. smegmatis mutants.  (all MIC50 values are expressed in µM) 
M. bovis  BCG Strains Compound X MIC50 CorA Mutations Mapped
wild-type 1.73 No Mutation
1 23.24 Met300 --> Val300
2 19.69 Met300 --> Val300
6 16.51 Gly299 --> Ser299
7 10.44 No Mutation
10 15.60 Ala317 --> Ser317
13 20.79 Ala317 --> Ser317
M. bovis  BCG Strains Compound Y MIC50 CorA Mutations Mapped
wild-type 0.36 No Mutation
1 0.625-1.25 Ala313 --> Gly313
2 1.07 Ala317 --> Ser317
M. smegmatis  Strains Compound Y MIC50 CorA and CorA-like Mutations Mapped
wild-type 1.47 No Mutation
1 >40 No Mutation
2 >40 No Mutation
4 >40 No Mutation
9 >40 No Mutation
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vector (see Figure 3.6A).  Recombinant BCG were selected out on Middlebrook 7H10 
plates with 25µg/ml kanamycin alone or 25µg/ml kanamycin with 5µM or 10µM of 
CpdX.  We isolated recombinants at all concentration of CpdX for BCG transformed 
with the mutant corA construct.  Despite a similar transformation efficiency, no wild-
type corA expressing recombinants that displayed resistance to CpdX were isolated. 
 
Upon introduction of a compound-resistant copy of corA gene into wild-type BCG, the 
bacilli showed an increase in MIC50 values for CpdX to nearly over 14µM (this is 
comparable with the compound-resistant mutant itself).  However, expression of 
neither wild-type M. smegmatis corA nor wild-type BCG corA resulted in such an 
increase in resistance to CpdX (MIC50 values of less than 4µM).  As a control, the 
empty vector control (pMV306 only) did not cause a change in MIC50 when 
introduced into wild-type BCG.  Conversely, we found that expression of wild-type 
corA carried on a plasmid in a CpdX-resistant background did not cause the mutant 
strains to become sensitive to CpdX.   
 
Taken together, this data suggests that CorA could be the target of CpdX or at least 
mediates a non-target specific mechanism of resistance.  The wild-type BCG has a 
compound-susceptible CorA that is blocked by CpdX thereby resulting in a low MIC50 
value.  However, upon expression of the compound-resistant CorA, the wild-type BCG 
develops a mutant phenotype, despite CpdX still inhibiting the wild-type CorA.  The 
only logical explanation for this is that the mutant CorA gene product is functional and 
has a dominant phenotypic effect.  In other words, the mutant CorA channel provides 
another avenue through which magnesium and other essential divalent cations can still 
enter the bacterium even in the presence of CpdX.  For CorA to be the target of CpdX, 
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it would be required to establish the essentiality of magnesium transport through CorA 



































































































Figure 3.2: Expression of corA gene in wild-type M. bovis BCG.  A shows a plasmid map of 
wild-type corA cloned into pMV306-Kan; all other constructs are similar except for the ‘corA’
region.  B shows the result of expression of the variants of corA gene into wild-type M. bovis
BCG and mutant M. bovis BCG.  (MIC50 values are expressed in µM; error bars indicate 
standard error; WT denotes wild-type; MT denotes mutant; Smeg denotes M. smegmatis corA) 
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3.6. Sequence alignment of the corA gene from various mycobacteria 
The rationale behind the alignment of the corA gene of various species/strains 
belonging to the Mycobacterium complex is that we wanted to determine if there was 
any genetic explanation for the high MIC50 of CpdX in M. smegmatis, but low MIC50 
in BCG.  In other words, we wanted to determine if M. smegmatis had a ‘natural 
mutation’ that conferred resistance to CpdX but not CpdY. 
 
We aligned the publicly available sequences of a selected number of species in the 
mycobacterial complex to determine the homology of corA within this group.  We 
found that M. smegmatis had different residues at 299, 300 and 313 as compared to 
M. bovis and M. tuberculosis sequence of CorA.  These ‘natural mutations’ are 
G299A, M300V and A313V, respectively.  We observed that the intrinsic resistance of 
M. smegmatis to CpdX could be due to a natural mutation at position 300 from a polar 
amino acid methionine to a non-polar valine.  It is of particular interest to note that 











Figure 3.3: Comparison of the corA sequences from various mycobacteria.  A shows the multiple 
alignment of the annotated corA sequences of these species.  Of particular interest, note amino acids 299, 
300, 313 and 317 (more discussion in text; M.tb denotes M. tuberculosis).  B shows the amino acid 
substitutions in the M. bovis BCG mutants and the ‘natural mutation’ in the M. smegmatis sequence from 
the wild-type M. bovis BCG.  The side-chain of these amino acids are also shown. 











B Amino Acid Position
299 G —H A —CH3 S —CH(NH2)—COOH
300 M —CH2—CH2—S—CH3 V —CH2—OH V —CH2—OH
313 A —CH3 V —CH2—OH G —H
317 A —CH3 A —CH3 S —CH(NH2)—COOH
M. smegmatis M. bovis BCG  mutantM. bovis  BCG
299 300 313 317
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3.7. Proteomics of Compound X-resistant M. bovis BCG mutant and wild-
type M. bovis BCG with and without Compound X treatment 
A proteomics approach was taken to identify the global differences in protein 
expression profile of wild-type BCG versus mutant BCG in the presence or absence of 
CpdX.  This involved the separation of proteins according to their pI (isoelectric point) 
and MW (molecular weight).  Following silver staining, differences in staining 
patterns were determined and the protein spots identified by LC-MS.  The trypsin-
digested proteins were compared to the known mycobacterial complex database using 
MASCOT and X! Tandem.  The comparison of compound exposure versus non-
exposure in wild-type bacilli could give us an indication as to which pathway is 
affected by the compound.  For example, a series of enzymes are involved in the 
production of an essential chemical/nutrient.  If the last enzyme was blocked by the 
compound then there could be an up-regulation of the protein expression of some (if 
not all) up-stream enzymes in the biosynthetic pathway.  Conversely, these proteins 
would not be up-regulated in the mutant following drug exposure because the  mutant 
is resistant to compound. 
 
We identified nine out of the ten spots that were sent for LC-MS analysis (see Table 
3.6).  These were superoxide dismutase (possibly increased with treatment in wild-type 
and mutant), a probable ABC-type transporter ATP-binding protein (increased with 
treatment in wild-type and absent in mutant), gene product of Rv1109c (possibly 
increased with treatment in wild-type), gene product of Rv2699c (increased with 
treatment in wild-type), thioredoxin peroxidase (possibly increased with treatment in 
wild-type), phosphoribosyl isomerase A (slight increased with treatment in wild-type) 
and a probable peptidyl-isomerase cis-trans isomerase A (possibly decreased with 
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treatment in wild-type).  Note that these results are preliminary, however, the results 
do give proteome profiles of wild-type BCG and mutant BCG that can be used for 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   














   










































































































































































































































































































Figure 3.5: 2D gel electrophoresis (18cm pH 4-7 strips).  A, B, C and D are 2D gels of total wild-type 
M. bovis BCG proteins, while E and F are from CpdX-resistant M. bovis BCG mutant.  B, D and F are 
without CpdX treatment.  A was treated with 0.6µM of CpdX for 3 days.  C and E were treated with 









Figure 3.6: 2D gel electrophoresis (18cm pH 4-7 strips) – close up 1.  A-F labels are as in Figure 3.14. 
Red arrow: spot number 9; Blue arrow: spot number 1; Green arrow: spot number 10; Black arrow: spot




























Figure 3.7: 2D gel electrophoresis (18cm pH 4-7 strips) – close up 2.  A-F labels are as in Figure 





























4.1. Physiological role of CorA 
Magnesium is an essential cofactor of many enzymes involved in central metabolic 
pathways that are required to maintain bacterial viability.  This includes reactions 
involving ATP as well as tRNA synthesis in both prokaryotic and eukaryotic systems 
(Cowan, 1998; Quigley et al., 1978; Szegedy and Maquire, 1999).  Moreover, it has 
also been shown that magnesium contributes to the stability of biological membranes 
(Szegedy and Maquire, 1999).  Hence, bacteria have developed multiple high-affinity 
magnesium transport systems to import this important divalent cation.  In 
mycobacteria, these transport systems include the magnesium and cobalt transport 
transmembrane protein (CorA encoded by Rv1239c), magnesium transport P-type 
ATPase C (MgtC encoded by Rv1811) and magnesium transport transmembrane 
protein (MgtE encoded by Rv0362).  Of all the known magnesium transport systems, 
CorA is thought to be the universal and most widely used system in both domains of 
bacteria as well as archaea.  
 
In Salmonella typhimurium, it has been shown that ion transport through CorA is 
bidirectional (Smith and Maguire, 1993).  The membrane potential of over -120mV 
creates an electrochemical gradient that drives magnesium inwards through CorA 
channel.  CorA only mediates the outward flow of magnesium ions only when 
extracellular [Mg2+] (magnesium concentration) exceeds 1mM, though the significance 
of this efflux is uncertain (Smith and Maguire, 1998).  However, the P-type ATPase 
magnesium transporters (such as mgtC) are known to mediate influx only and are 
expressed under conditions of low extracellular [Mg2+] (Smith and Maguire, 1998).  In 
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M. tuberculosis, mgtC is not necessary for the invasion of macrophages but is required 
for survival inside these phagocytic cells (Buchmeier et al., 2000). 
 
The corA gene from M. tuberculosis Erdman has been shown to be non-essential as it 
could be deleted in an earlier study (Sareen et al. 2003).  This data is further supported 
by Himar1-based transposon mutagenesis studies in M. tuberculosis H37Rv in which 
corA was found to be non-essential (Sassetti et al., 2003).  Given the presence of other 
cation transporters, mycobacteria can still survive by relying on other magnesium 
transporters under in vitro conditions where levels of this cation are high (although 
mgtC is expressed only under low extracellular [Mg2+] conditions). 
 
In 2006, two groups expressed and crystallized the homo-pentameric closed-
conformation CorA channel of T. maritima (Eshaghi et al., 2006; Lunin et al., 2006).  
This transporter has a narrow entrance (5Å) that opens up into the cytoplasm to 
approximately 20Å.  Magnesium ions would have to travel at least 40Å to enter the 
cell and it was also shown that the channel pore comprises of two cavities created by 
three constricted regions.  These three constricted regions are formed by amino acids 
residues B314, M302/T305 and L294/M291, respectively.  The CorA transporter can 
transport around 10 million ions per minute.  This is considerably slower than 
potassium channels, which can allow around 100 millions ions to pass through per 
second.  This could be due to the fact that the CorA channel comprises of five subunits 
whereas magnesium needs to be hexacoordinated for transport.  The fact that hydrated 
magnesium has the largest diameter of all biological ions (~5Å) and that the similarly 
sized but 3+-charged cobalt(III)hexaammine is an inhibitor of CorA, it is clear that 
CorA does not rely on the charge nor hydrated size in its selectivity to transport ions 
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(Kucharshi et al., 2000; Eshaghi et al., 2006; Lunin et al., 2006).  The authors suggest 
that, since magnesium has a hydrated radius about 350 times larger than its atomic 
radius, a selective filter based on this size difference would be very effective.  
Moreover, CorA is also known to transport cobalt and nickel ions, but not manganese, 
presumably, because manganese ion is significantly larger than cobalt, nickel and 
magnesium.  In addition, the cobalt(III)hexaammine is about the same size as a fully-
hydrated magnesium and yet cannot pass through the CorA channel.  It should be 
noted that the three-dimensional structure could still be relevant for other prokaryotic 
and eukaryotic species because, despite little sequence homology, the secondary 
structure of many species are quite similar to the T. maritima CorA (Figure 4.2).  The 
CorA of M. tuberculosis shows 28% identity at the protein level with T. maritima 
CorA (accession number NP_228371). 
 
The key question though is whether magnesium transport via CorA is essential under 
physiological conditions (i.e. inside the human host) and this remains to be 
determined.  In Helicobacter pylori, a corA gene deletion mutant was isolated and was 
unable to grow in media without magnesium (it requires supplementation with at least 
20mM of magnesium).  Given the low magnesium concentration within the human 
host, the authors concluded that CorA is essential for the survival of this gastric 
pathogen under in vivo conditions (Pfeiffer et al., 2002).  We demonstrate here that 
CpdX-resistant mutants of BCG showed slightly slow growth (as measured via 
turbidimetry) than the parental strain (data not shown).  In addition, it would be 
interesting to see if the requirement of magnesium for growth increases in BCG and M. 
tuberculosis corA knock-out mutants. 
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Figure 4.1: Target theory versus mode of entry theory.  This figure highlights the way in which the 
wild-type strains are killed by compound X and how they could escape the bactericidal effect of the 
compound by mutating the CorA channel according to the target theory and the transporter theory. 
4.2. Is CorA the mode of entry or the target for CpdX and CpdY? 
Since CorA is a channel to transport various ions, including cobalt and magnesium, 
two hypotheses were developed in regards to, (1) CorA being the actual drug target of 
CpdX or (2) CorA merely serves as a channel through which the compound enters the 
bacteria.  In addition, it is also possible that the CorA protein is neither the target nor 
the entry channel and that the mutation in CorA mediates a non-target specific 











4.2.1. Target theory 
In this theory, we hypothesize that CpdX blocks the CorA channel and hence inhibits 
the entry of various divalent cations, including primarily magnesium but also cobalt 
and nickel.  For this theory to be true, we have to prove that magnesium transport via 
corA is an essential process for mycobacterial growth in vitro and survival in the 
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human host.  In addition, we also have to show that the exposure of mycobacteria to 
CpdX results in reduced magnesium or cobalt transport. 
 
As shown earlier, the expression of mutant corA gene driven by its own promoter on a 
plasmid confers resistance to CpdX in wild-type BCG.  In contrast, expression of the 
wild-type BCG corA or the wild-type M. smegmatis corA gene had no effect on this 
phenotype.  Similarly, expression of wild-type corA in the BCG mutant strain did not 
result in the bacteria reverting to sensitivity.  Therefore, it can be concluded that the 
mutant phenotype is dominant in the presence of CpdX because, as long as there is a 
functional corA gene the bacilli will grow unimpeded.  This evidence is supportive of 
the theory that CorA is the biological drug target of CpdX.   
 
To establish the essentiality of magnesium transport, we will have to develop a 
functional assay to measure the intracellular [Mg2+] in BCG to determine if CpdX 
affects the movement of magnesium into and out of the cells.  We could utilize the 
magnesium-specific fluorescent dye mag-fura 2 (acetoxymethyl ester form) to measure 
free magnesium levels with and without the treatment of BCG cells with CpdX 
(Froshauer et al., 2004).  This protocol for the measurement of magnesium levels has 
traditionally been applied to measure concentrations of free magnesium within cells or 
organelles of eukaryotic cells; and more recently in Salmonella enterica (Froshauer et 
al., 2004).  We would perform this experiment with five strains of bacteria, wild-type 
BCG, CpdX-resistant BCG, corA deletion mutant of BCG and corA knock-out BCG 
complemented with either wild-type corA or mutant corA gene on a plasmid.  With 
each strain, we would measure the effect of addition of extracellular [Mg2+] with or 
without the addition of CpdX. 
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Figure 4.2: Target versus Transporter theory when M. bovis BCG is complemented with mutant 












However, we can delete the corA gene under laboratory conditions in M. tuberculosis 
and BCG (suggesting the gene is non-essential under the in vitro conditions) (data not 
shown) (Sareen et al., 2003).  Nevertheless, the mere growth of this mutant in 
laboratory media may not reflect the importance of this gene product for intracellular 
survival in the host macrophages.  To this end, we will be creating a BCG corA 
deletion mutant and test its ability to grow in macrophages and mice.  The growth 
phenotype of the corA mutant in these models will be compared with that of wild-type, 
to determine if corA gene is important for in vivo survival.  Nevertheless, due to the 
high bactericidal activity of the compounds in vitro, we believe that the biological 
target should be essential under in vitro conditions (i.e. the gene cannot be deleted).  
This suggest that CorA, although is a mediates resistance, could not be the biological 
target of CpdX and CpdY. 
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4.2.2. Mode of entry theory 
We also hypothesized whether CorA could be a channel or pore through which the 
compound enters the bacterium and inhibits the ‘real’ target.  The obvious question 
one would ask is – why would the bacterium mutate a channel protein and not the real 
target?  Since this hypothetical ‘real’ target must be essential (based on the bactericidal 
activity of CpdX and CpdY), any mutation could be detrimental to its function and 
cause cessation of growth.  However, according to this theory, the mutation of corA 
gene does not lead to bacterial death and, at the same time, block the entry of 
compound and hence it is a much more favorable option for the bacteria. 
 
The biological target of any bactericidal compound/drug, by definition, has to be 
essential because if it is not essential then inhibition of the target should not have a 
phenotypic effect, i.e. death of bacteria.  Genetic knock-out studies (Sareen et al., 
2003) and Himar1-based transposon mutagenesis studies in M. tuberculosis have 
already shown that corA is non-essential for growth under in vitro conditions.  This 
would suggest that the target for CpdX is another protein/enzyme and not the CorA 
gene product.  It could be argued that since Middlebrook 7H9 broth has around 160µM 
of magnesium, the corA deletion mutant is able to grow by utilizing other magnesium 
transporters such as mgtC or mgtE (Piddington et al., 2000).  This, however, does not 
explain the potent bactericidal activity of CpdX on BCG. 
 
One could also propose strong arguments against this transporter hypothesis.  If CorA 
is the transporter of CpdX and CpdY, the expression of wild-type corA in mutant BCG 
should provide a means for the compound to enter and should result in reversion back 
to compound sensitivity.  This was not what was observed, in fact the bacteria 
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remained resistant.  The transporter hypothesis can be disproved using a corA knock-
out because, if this hypothesis is true, with the deletion of CorA, the compound cannot 
enter and will hence appear to have lost its activity.  The research groups that 
crystallized CorA in T. maritima, suggest that the magnesium ion enters the bacteria in 
a partially dehydrated state (Eshaghi et al., 2006; Lunin et al., 2006).  The Leu294 
constriction in T. maritima CorA results in a mere 2.5Å making it unlikely for a 
500g/mol compound (CpdX) to enter into such a small pore that has been shown to 
transport dehydrated magnesium under normal physiological conditions (Payandeh and 
Pai, 2006).  It should be noted though that the protein was crystallized in a closed 
conformation and the pore could open up significantly in the open conformation. 
 
4.2.3. Other hypotheses – Only a Mechanism of Resistance? 
The non-essentiality of the corA gene and the results of the corA over-expression 
experiments suggest that there could be an alternative genetic explanation for a corA 
gene mutation mediating resistance to CpdX.  Since, our mutant isolation studies were 
based on one single phenotype, resistance to the compound, we cannot rule out the 
possibility that CorA is not the target but is just an indirect resistance mechanism.  It is 
possible that, via mechanisms that are still unknown, the mutation in corA gene leads 
to, for example, changes in the cell wall or alters a signaling pathway or restricts 
magnesium availability leading to the development of resistance to CpdX.  The 
essential ATP binding ABC transporter (Rv1463) that was shown to be up-regulated 
upon drug exposure using 2D gels is a candidate gene that can be further evaluated.  
We have also plated out the A317S CpdX-resistant BCG mutant on Middlebrook 7H10 
plates containing 50µM and 80µM of CpdX in order to isolate mutants with high level 
of resistance.  Moreover, drug-resistant mutants can also be isolated using the corA 
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deletion BCG mutant.  These strains will be sent for CGS and, if we are successful in 
identifying another gene that can confer compound resistance, this could be the real 
biological target.  Similarly, given that the corA gene was not mutated in the M. 
smegmatis CpdY-resistant mutants, this suggests that there could be another putative 
drug target that could be identified by sequencing.  However, comparative genome 
sequencing may not be possible at this stage for M. smegmatis because the annotation 
of the whole genome is yet to be completed.  To design effective CGS chips, it is 
required for the whole genome sequence of the target organism to be completed.  
Hence, at this stage, we can only resort to the classical molecular biology technique of 
library screening (both wild-type and mutant libraries) to elucidate another candidate 
biological target in M. smegmatis that would subsequently be validated using 
biochemical and genetic techniques. 
 
4.3. Differences in the proteome derived from wild-type and mutant M. bovis 
BCG 
The proteomic profiling of wild-type BCG versus mutant BCG in the presence or 
absence of CpdX revealed several protein spot intensity differences. These include, 
superoxide dismutase (encoded by Rv2946) which has previously been shown to be 
up-regulated during heat-shock response and in a starvation model of M. tuberculosis 
(Stewart et al., 2002; Betts et al., 2002).  An hypothetical protein (Rv2699c) and an 
essential ATP binding protein ABC transporter (Rv1463) were also found to be up-
regulated during heat shock response and during nutrient starvation, respectively 
(Betts, 2002; Sassetti et al., 2003).  Our results suggest that all three of these proteins 
were up-regulated with CpdX treatment.  These results were expected since CpdX has 
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potent bactericidal activity on BCG and therefore we anticipated that the bacilli would 
express non-specific stress-related proteins/enzymes. 
 
Microarray profiling of M. tuberculosis to CpdX exposure was done in collaboration 
with Dr. Clifton Barry (National Institutes of Health, USA), showed sigE, sigD and 
sigH genes to be up-regulated.  SigE has previously been shown to be up-regulated at 
the mRNA level under stress conditions (specifically exposure to 0.05% of SDS) and 
takes part in the heat-shock response as shown by real-time quantitative PCR 
(Manganelli et al., 1999; Stewart et al., 2002).  The product of oxidative stress-
regulating gene sigH that regulates sigE was also up-regulated in an earlier study 
(Raman et al., 2001).  Manganelli et al. (1999) also discovered that sigD is a sigma 
factor that is up-regulated at the mRNA level following heat-shock.  Moreover, the 
superoxide dismutase (Rv2946) and thioredoxin peroxidase (Rv1932) proteins 
identified in our studies are known to destroy free radicals generated during oxidative 
stress. 
 
Phosphoribosyl isomerase A (Rv1603), which catalyzes the fourth step of the essential 
histidine biosynthesis pathway, was also slightly up-regulated upon exposure to CpdX 
at the protein level in wild-type BCG, but not at the mRNA level.  Based on the 
bactericidal activity of CpdX or CpdY, it could be anticipated that the target for these 
compounds should be an essential gene.  For example, the inhibition of an essential 
amino acid biosynthetic pathway would inhibit the ability of the bacteria to multiply 
by removing one of its key building blocks.   
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Interestingly, all the genes in Table 3.6 excluding thioredoxin peroxidase, are found in 
the degenerate genome of the pathogen, M. leprae.  This extremely slow-growing 
mycobacterium cannot be cultured in vitro and is believed to have undergone reductive 
evolution where genes not required for survival have been removed (Garnier et al., 
2003 and Cole et al., 2001; Eiglmeier et al., 2001).  In fact, the M. leprae genome is 
approximately 3.27Mb in size compared to the 4.41Mb genome of M. tuberculosis.  
Furthermore, in the M. leprae genome, over 1,100 genes are considered pseudogenes 
and are not functional.  This suggests that, despite the fact that many of the genes in 
Table 3.6 can be disrupted by transposon mutagenesis in in vitro conditions, these 
genes themselves could still play some functional role in mycobacterial survival or 
pathogenicity under in vivo conditions.   
 
Overall, the proteomics approach has led to the identification of primarily heat-shock 
or starvation factors being up-regulated following exposure to CpdX.  The essential 
enzyme phosphoribosyl isomerase A, involved in histidine biosynthesis, was shown to 
be up-regulated at the protein level with CpdX exposure.  The biological reason for 
this up-regulation requires further experiments and analysis.  This data, along with 






























In the present study, we have successfully isolated spontaneous resistant mutants to 
Compound X (CpdX) and its derivative Compound Y (CpdY) in both the slow-
growing M. bovis BCG and fast-growing M. smegmatis.  Using comparative genome 
sequencing and subsequent confirmation by sequencing several resistant clones, we 
have shown that resistance to CpdX and CpdY arises due to a single amino acid 
substitution in the universal magnesium transporter CorA.  The ability of parental M. 
bovis BCG strain to acquire resistance to CpdX following the introduction of a mutant 
copy of the corA gene suggests that the corA gene could be the putative target for this 
compound class.  Conversely, the introduction of the wild-type copy of the corA gene 
into the mutant M. bovis BCG did not reverse the phenotype to sensitivity, possibly 
because of the dominance of the mutant phenotype.  Nevertheless, this has to be 
confirmed with live measurement of magnesium fluxes using a corA gene deletion 
mutant.  On the other hand, corA has been shown to be non-essential under in vitro 
conditions because it can be deleted without losing viability.  It is possible that another 
gene product is the actual gene target and that corA confers resistance via an yet 
unknown mechanism.  In order to gain more knowledge about the biological target, we 
also employed transcriptomic and proteomic-based profiling of wild-type and mutant 
M. bovis BCG with and without CpdX treatment.  From these systems biology 
approaches, we identified mainly genes involved in the heat shock response, and genes 
known to be up-regulated during starvation or oxidative stress.  A forward chemical 
genetics approach is an attractive method for the identification of novel biological 
targets in mycobacteria and these novel targets could be utilized in future high-
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Appendix I:  Comparative Genome Sequencing 
 
This file explains the data output from the CGS process and modified from the file 
provided by NimbleGen Inc. (USA). 
 
NOTE:  For organisms with genomic G/C content of >60%, such as Mycobacterium or 
Pseudomonas species, please note that the resequencing step often has a high false 
positive rate, calling more than 100 false positive SNPs per genome analysis. To 
eliminate the majority of these false positive, please look at the “HIGHEST__RANK” 
column in the <Samplename>_snp_info.txt, SNPs with “HIGHEST__RANK” scores 
above 10,000 are most likely to be real, and any score below 1, are likely to be false 
positives.  
 
Genome Mapping: <Samplename>_ratio.gff (see Figure 3.2: Top Panel) 
 
Genome Resequencing: <Samplename>_snp_info.txt (see Figure 3.2: Bottom Panel) 
 
<Samplename>_ratio.gff 
The <Samplename>_ratio.gff file is designed to be viewed using NimbleGen’s 
SignalMap visualization software. This viewer allows the data from the entire genome 
to be easily browsed. It contains data “tracks” that indicate the positions of SNPs and 
other potential mutations, as well as raw data.  A users manual for SignalMap (in PDF 
format) is available from NimbleGen if one was not delivered with the Software. The 
following data tracks may or may not be present, depending on the availability of 
genome annotation and resequencing information: 
 
Genome Annotation (generally named with the genome identifier, typically the RefSeq 
number if available):  Displays colored blocks representing annotated genes. Blocks 
above the line indicate genes encoded on the forward strand of the genome, while bars 
below the line represent genes encoded on the reverse strand. The CDS data field from 
the Genbank annotation file is used to generate this track. If the Genbank file was 
annotated with hyperlinks, double-clicking on a gene block will open a web browser 
and target the NCBI database for know information about the selected gene. If no 
Genbank annotation file was available at the time of analysis, this track will be absent.  
 
DIFFERENCES_<samplename>: The track will only be displayed if resequencing was 
not performed. Indicates positions in the genome that have a significant ratio shift 
between reference and test probes for both strands. These positions may represent 
SNPs, deletions, sites of insertion, the end points of inversions or translocations. It is 
sometimes possible to distinguish mutation signatures. Deletions tend to have large 
ratio shifts, while SNP ratio shifts tend to be subtler. The number of consecutive 
probes shifted by any mutation will allow for an estimation of its size, based on the 
mapping probe spacing. Most of the mutations represented by SNPs can be resolved by 
performing follow up resequencing array analysis, as long as the genomes do not 
appear to be too divergent (>0.5%). 
 
SNP_<samplename>: This track is only displayed if resequencing was performed. 
Displays colored coded points or vertical bars that indicate the position of SNPs (base 
substitutions) identified in the genome by resequencing. If the data is displayed as 
93 
points, it is highly recommended that the track style is changed to bars, by right 
clicking on the left side of the y-axis for this track, selecting style, and clicking on 
bars. This will make the SNP positions much easier to visualize. SNP positions are 
colored light blue if they fall between annotated genes, green if they fall inside a gene 
but does not change the amino acid sequence of the encoded protein (synonymous 
mutation), and dark blue if the SNP changes the amino acid sequence of the encoded 
protein (non-synonymous mutation). Holding the cursor over the SNP position will 
display the nucleic acid and amino acid changes at the top of the screen.  
 
NON_CALLED_RIO_<samplename>: This track is only displayed if resequencing 
was performed. Displays positions in the genome that have a significant ratio shift 
between reference and test probes for both strands, but were not called SNPs by 
resequencing. These positions may represent non-SNP mutations, such as deletions, 
sites of insertion, the end points of inversions or translocations, tightly clustered SNPs, 
or individual SNPs that were not called reliably by resequencing. The number of 
consecutive probes shifted by any mutation will allow for an estimation of its size, 
based on the mapping probe spacing. The exact nature of these positions can be 
obtained by other techniques, such as PCR amplification followed by capillary 
sequencing. 
 
RESEQUENCED_<samplename>: This track is only displayed if resequencing was 
performed. Displays positions in the genome that were interrogated by resequencing 
arrays.  
 
RATIO_<samplename>: Plot of the probe intensity ratio (Reference/test). Reference 
probes and test probes that do not span a mutation should represent full-length perfect 
match hybridization, and thus should have similar intensities, with a reference/test ratio 
near 1. Probes that span mutations in the test genome typically display lower 
hybridization intensities than the corresponding reference probes, and thus the 
reference/test ratio will shift above 1. If the test genome contains an amplification 
event (increased copy number when compared to the reference), then the reference/test 
ratio will shift below 1.  
Note: If the reference genome used to design the arrays is different from the actual 
reference used in the experiment, the reference probe intensity values may not 
represent full-length perfect match hybridization signal. These regions may not provide 
enough signal to allow robust data generation. 
 
AVE_TEST_<samplename>: Plot of the average of the forward and reverse probe 
intensities from the test genome hybridization. 
 
AVE_REFERENCE_<samplename>: Plot of the average of the forward and reverse 
probe intensities from the reference genome hybridization. 
 
<Samplename>_snp_info.txt 
The snp_info file provides information on SNPs that were identified in the genome. 
The data columns produced by the SNP analysis are provided below. 
 
SEQ_ID: The genome identifier, typically the RefSeq number if available. 
 
GENOME_POSITION: The genomic position of each SNP. 
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REF: The reference nucleotide of each SNP.  
 
SNP: The mutant nucleotide of each SNP. 
 
CONFIDENCE: A composite of several parameters to determine the likelihood that 
any SNP is real (not a false positive). This score is based on the quality of the SNP call 
and the similarity of the sequencing flanking the SNP to other sequences in the 
genome that may cross hybridize. SNPs with HIGH confidence scores have a high 
probability of being true SNPs. LOW confidence scores generally result from failed 
uniqueness testing, and have a very high likelihood of being false positive base calls. 
These sites should generally be ignored. SNPs with MEDIUM confidence should be 
validated by capillary sequencing before biological conclusions are drawn.   
 
PROBABILITY: A relative measure of the quality of a SNP call. The score typically 
ranges between 1.0 and 0.9.  The lower the probability score, the less likely a SNP is to 
be real. This criterion alone should not be used to assign SNP calls. SNP loci that are 
not unique in the genome often have excellent probability scores and are still often 
false positive.  
 
TYPE: Lists whether or not a SNP is found within an annotated gene, or between 
annotated genes. SNPs in genes are designated as coding, and are listed first. SNPs 
between genes are designated as intergenic, and are listed second.  
 
NMER_SCORE: A weighted measure of how often perfect matches for increasing 
numbers of central bases in each probe are found in the genome is calculated: the 
“Nmer frequency”. Each such perfect match contributes to the Nmer frequency score, 
with shorter oligos contributing less than longer oligos according to the following 
equation: 
 
Nmer frequency score =  [N-mer frequency]*[0.75^((29mer-Nmer length)/2)] 
 
The sum of the frequency scores for central Nmers from 19, 21, 23, 25, 27, and 29mers 
is calculated for each Probe calling a SNP. The higher the Nmer frequency score, the 
more likely it is that the probe will also hybridize elsewhere in the genome. Any SNP 
being called by a probe with an Nmer frequency above zero is considered a potential 
false positive. 
 
UNIQUE: The second uniqueness test calculates a “sequence dissimilarity” score that 
is calculated by comparing the 29 bases spanning the SNP to every possible 29 base 
window in the reference genome. Mismatches rear the end of a probe tend to disrupt 
hybridization less than centrally located mismatches, and hence are weighted 
differently. The weight value vs. position used in this score are listed below: 
 
1 2 3 4 5 6 7 8 9 1011121314151617181920212223 24 25 26 27 28 29
1 1 1 2 2 2 2 4 4 4 4 4 4 4 0 4 4 4 4 4 4 4 2 2 2 2 1 1 1 
 
The dissimilarity score for each possible 29mer in the genome is calculated by adding 
up the weight vectors for each base not matching its corresponding base in the 29 bases 
surrounding a SNP. If the lowest dissimilarity score for every 29mer in the genome is 
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greater than 10, the SNP position is considered unique. For example, if the 29mer that 
most closely matches the 29 bases surrounding a SNP contained 3 mismatches 
between positions 8 and 22, that SNP position would have a dissimilarity score of 12 
(4+4+4), and be sufficiently dissimilar to be considered unique, whereas six 
mismatches in positions 1 to 6 would not meet the uniqueness threshold of 10 
(1+1+1+2+2+2 = 9). SNP sites that pass this criterion (threshold value >10) are given 
a passing score of 1, while SNP sites that fail (threshold value <10) are given a failing 
score of 0. SNP sites that fail this criterion are considered potential false positives. 
 
HIGHEST_RANK: A measure of how strongly the SNP position was indicated by the 
mapping data. Ranks above 10,000 are strongly indicated by both strands, whereas 
numbers between 10,000 and 1 were only strongly indicated a probe from one strand. 
Rank scores below 0 were not strongly mapped by either strand. Occasionally true 
SNPs are identified by resequencing that were not strongly indicated by mapping.  
NOTE:  For organisms with genomic G/C content of >60%, such as Mycobacterium or 
Pseudomonas species, please note that the resequencing step often has a high false 
positive rate, calling more than 100 false positive SNPs per genome analysis. SNPs 
with “HIGHEST__RANK” scores above 10,000 are most likely to be real, and any 
score below 1, are likely to be false positives. 
 
FORWARD: The average probability score of the five base calls in either direction 
from the SNP on the forward strand. This is a measure of the SNP “neighborhood” 
quality.   
 
REVERSE: The average probability score of the five base calls in either direction from 
the SNP on the reverse strand. This is a measure of the SNP “neighborhood” quality.   
 
FORWARD_INTENSITY: The raw intensity of the probe that called the SNP on the 
forward strand.  
 
REVERSE_INTENSITY: The raw intensity of the probe that called the SNP on the 
reverse strand. 
  
AA CHANGE: Categorizes coding SNPs base on whether or not they change the 
amino acid sequence of a protein. SYN indicates synonymous SNPs (no amino acid 
change). NON indicates nonsynonymous SNPs (altered amino acid).  
 
ORIG_AA: The amino acid associated with the reference sequence for the 
corresponding SNP position.  
 
SNP_AA: The amino acid associated with the test sequence, for the corresponding 
SNP position. 
 
GENE_POSITION: The nucleic acid position mutated within a gene.  
 
LOCUS_TAG: The locus tag field from the Genbank annotation file.  
 
START: The genomic start position of the mutated gene. 
 
END: The genomic end position of the mutated gene. 
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STRAND: The genome strand on which the mutated gene is located.  
 
PRODUCT: The annotation field from the Genbank file.  
 
NOTE: The note field from the Genbank file.  
 
